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Introduction 
  
                                                 1.0. INTRODUCTION 
               Microorganisms play an important role in human body. They have mutual 
relationship with the host. They are either beneficial or pathogenic to the host. Among 
them, bacteria plays major role in causing a wide variety of infections in humans.     
               Urinary tract infections (UTIs) are the most common bacterial infections
1
 
affecting approximately 150 million people worldwide
2 
who need medical care, whereas 
in hospitals, they are the most common nosocomial infections accounting for about 30% -
40%
3
.   
                About 10% of humans develop UTI in chilhood
4
. During the first year of life, 
the prevalence of UTI is around 2% in both females and males
5
.  After    that, it is 
reduced in males and increased in females. UTI is predominantly a disease of females in 
reproductive age group. About 40-50% of women in the reproductive age group have had 
history of at least a single episode of UTI in their lifetime
6
. Predisposing factors for UTI 
depends on age, gender, race, nutritional factors
7
, hygiene and immune status of the 
patients. The high prevalence of UTI in females could be due to the anatomical structures 
like shorter urethra and its closeness to the anus
8
 which allows the entry of pathogen by 
fecal-perineal-urethral contamination. UTI during pregnancy is due to stasis of urine in 
the ureters, pressure effects and hormonal changes
9
. Moreover, 25% of untreated women 
in pregnancy have asymptomatic bacteriuria (ASB) and pyelonephritis
10
. Unprotected 
sexual intercourse, poor hygiene and childbirth also contribute to recurrent UTI in 
females
11
. Post-menopausal women have higher incidence for UTI due to uterine 
prolapse, less estrogen activity, altered vaginal biota and associated co- morbid condition 
like diabetes mellitus (DM)
12,13
.  
                In males, the UTI is common at extremes of life. After infancy, the incidence is 
low but it is complicated at older age due to prostate enlargement and co-morbid 
conditions
14
. 
                Prolonged hospital stay due to other medical and surgical problems and urinary 
catheterization are the most important risk factors in older age of both sexes.   
               Based on the organs affected and clinical layout, they are grouped as upper 
UTI versus lower UTI and complicated versus uncomplicated UTI
15
.   Based on the 
presence or absence of symptoms, it has been classified into asymptomatic bacteriuria 
(ASB) and acute symptomatic UTI which further includes acute and chronic 
pyelonephritis, cystitis and urethritis in males and females, prostatitis in males
16,17 
. 
Depending on the number of episodes of UTI and treatment response, it is classified into 
recurrent infection/ reinfection, relapse and treatment failure
18
. Depending on the source 
of pathogen, it has been categorized into community acquired and hospital acquired UTI.  
              E.coli is the most common cause of uncomplicated UTI and causes 85% 
community acquired and 50% of hospital acquired infections (HAI) 
19
. Other 
Enterobacteriaceae group, Staphylococcus spp, Enterococcus spp, Pseudomonas 
aeruginosa are the next most common causes. Mycobacterium tuberculosis, Chlamydia 
trachomatis, Candida species are other rare causes of UTI 
5,20
.  Rarely UTI may be 
caused by viruses or fungi
21
.  
                E. coli is the predominant commensal in the gastrointestinal tract which is the 
source for initiation of UTI. It has been proved that few consistent serotypes of E. coli 
causing UTI and hence was designated as uropathogenic Escherichia coli (UPEC). UPEC 
possesses its virulent property due to the presence of virulent genes carried by 
pathogenicity islands (PAIs), bacteriophages, transposons or plasmids
22
.  
       Virulence Markers (VM) of UPEC are categorized into 2 groups 
1) Cell surface  associated  VMs 
2) Secreted VMs  
The role of important virulence factors are  
 Capsular antigen – antiphagocytic action and serum resistance property. 
  Fimbriae help in the adhesion of organism to epithelial cell surface, thereby 
it escapes from flushing action during micturition. 
 Toxins like hemolysin and Cytotoxic Necrotising Factor (CNF) act by their 
cytotoxicity and invasiveness. 
 Production of siderophore by E.coli which takes up iron from the host and 
helps in colonization and survival of pathogen. 
  Biofilm formation over the epithelial cells and on any catheter devices is 
responsible for antibiotic resistance
23
. 
              Wide use of beta-lactam antibiotics empirically, prolonged intake of 
antibiotics for inappropriate duration and long term hospital stay lead to persistence and 
spread of virulent organisms (UPEC) and end up in a major threat called resistance. In 
Indian studies conducted by Singhal et al
 
, Mathur et al and Manchanda et al , the 
prevalence of Extended Spectrum Beta Lactamase and AmpC producing isolates was  
found in the range from 55% to 69%
24,25,26
.   Multi drug resistant (MDR) 
pathogens increase the morbidity and mortality of urinary tract infections in India
27
.
 
Therefore, regular monitoring of antibiotics resistance profile is very essential for 
treatment and also to prevent the spread of resistant strains in both hospital and 
community.   
                   Due to limited studies on virulence markers (VM) of UPEC causing UTI, the 
present study was undertaken to know the prevalence of UPEC, VMs identification   and 
its antibiotic sensitivity. It is hoped that this information will definitely help to reduce the 
morbidity, hospital stay and also will provide valid information for effective hospital 
infection control. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Aim and Objectives 
 
                                      2.0 AIMS AND OBJECTIVES 
1.  To know the prevalence of Urinary Tract Infections. 
 2. To isolate and identify Escherichia coli from UTI. 
3. To detect the Virulence Markers of Uropathogenic E.coli by phenotypic tests. 
4. To study the antibiotic susceptibility pattern using Kirby Bauer disc diffusion method 
and to estimate the antibiotic resistance rate.  
5. To detect the extended spectrum  lactamase (ESBL) strains by CLSI phenotypic 
confirmatory test. 
6. To analyze the association of virulence factors with co-morbid conditions and their 
resistance pattern. 
   
 
 
 
  
 
 
 
  
 
 
 
 
 
 
         Review of Literature 
3.0. REVIEW OF LITERATURE 
3.1. History of UTI: 
                     Urinary tract infections (UTIs) had caused a large outbreak long back, even 
before the bacteria were identified and recognized as the causative agents.  It was first 
mentioned around 1500BC
28
. They have been described since ancient times
 
and 
Egyptians defined UTIs as "sending forth heat from the bladder"
29
.  
Table: 1- Historical perspectives of UTI 
Sn
o 
Contributors Contributions  
1 Egyptians(Ebers papyrus) Documented UTI  for the first time 
2 Kahun papyrus Suggested hematuria(due to worm in the belly) 
3 Arabs  Introduced uroscopy 
4 Romans  Introduced surgery for renal calculi 
5 Hippocrates(19
th
 century) Introduced urine analysis as diagnostic  
Procedure 
6 Hippocrates (387 BC) Found the association between UTI, calculi  
and groin abscess. 
7 Wilhelm Duschan Lambl 
(1856) 
Published for the first time on use of 
 microscope in urine analysis 
                          
                    UTI caused high morbidity in the preantibiotic period. Hippocrates said that 
cystitis appears and could last for a year before either resolving or worsening to affect the 
kidneys.  Later on most of the UTIs were described and were thought to be the bacterial 
cause globally. They were gaining prevalence in many parts of the world. Many attempts 
were made to give the incidence rate of the infection. But accurate assessment was not 
possible since it was not a notifiable disease. Later it got many researchers’ attention to 
make their efforts in the study and to describe the causes, pathogenesis and treatment. 
                     Many earlier investigators suspected renal involvement was very silent and 
coined the term for urinary infection as “pyelonephritis lenta”.  They also stated them as 
persistent and insidious infection which could end up in End Stage Renal disease
30
.   In 
1956, Kass developed his criteria that UTIs was based on significant and asymptomatic 
bacteriria.  Kass contribution in this field encouraged many researchers to develop the 
epidemiological investigations. Next step of investigations in UTI was to develop definite 
marker. This was carried out with the basis of Kass contribution. Later Kass observed 
that the growth was inhibited by pH and urine osmolality
31
. Acute urethral syndrome 
which involved urethritis, vaginitis and cystitis was defined in 1980s
32
.
  
3.2. Epidemiology of UTI: 
                        UTI causes enormous morbidity in the general population, and is the most 
common cause of community and hospital acquired infections. 
            
                   Fig 1: Global prevalence of UTI (Wagenlehner F et al 2016)
33
 
                   The exact prevalence of UTIs is dependent on age, gender, socio economic 
status and other environmental factors. With advancing age, the incidence of UTI 
increases in males due to prostate enlargement and neurogenic bladder. About 20% of 
women experience a single episode of UTI during their lifetime, and 3% of women have 
more than one episode of UTI per year
34
. The association of UTIs with sexual intercourse 
may also contribute to infection because sexual activity increases the chances of bacterial 
contamination of the female urethra. Pregnancy also makes them more susceptible to 
infection. Recurrent infections are not uncommon, and it leads to irreversible damage of 
the kidneys, resulting in renal hypertension and renal failure in some. About 5% of 
catheterized patients develop bacteriuria, despite adequate aseptic precautions during 
instrumentation
35
 and in some it leads to septicemic death
36
. 
                                          
           Fig2: Prevalence of UTI among females (Brumbaugh AR et al.  2012)
37
 
3.3. Classification of UTI: 
 
 
 
 
 
              3.3.1.   Nosocomial UTI/ Health Care associated UTI : 
                            According to current definitions, more than 30% of nosocomial 
infections are urinary tract infections (UTIs). A UTI is defined 'nosocomial' (NUTI) when 
it is acquired in any healthcare institution after 48 h of admission, which may be 
associated with any of the following risk factors. 
Community acquired UTI and Nosocomial UTI 
Upper UTI and Lower UTI 
Complicated UTI and Uncomplicated UTI 
 
 Patients with indwelling urinary catheters(>48 hours) 
 Those  undergoing urological surgery and manipulations  
 Long-stay at hospital   
 Patients with debilitating diseases38   
                 Source of HA-UTI: patient’s endogenous flora, cross contamination from other 
patients or hospital personnel, by exposure to contaminated solutions or unsterile 
equipments.        
     3.3.2.    Community Acquired UTI: 
                   Episode of UTI may be detected at the time of admission or within the first 
48 hours. It may occur without the above mentioned risk factors. Mostly they are caused 
by Enterobacteriaceae and recently the trends changed that MDR uropathogens are the 
common causes. 
3.3.3. Upper UTI vs lower UTI:  
Table 2 : Comparison of Upper and Lower UTI 
 
Sites involved 
Lower UTI Upper UTI 
Urethra, Bladder Kidney, Ureter 
Route of spread Ascending route Both ascending and 
descending route 
Occurrence More common Less common 
3.3.4. Uncomplicated UTIs:  
             It occurs in patients with normal structural and functional urinary tract. Usually it 
is caused by antibiotic susceptible pathogens. It is seen in case of  
 Immunocompetent patients  
 No co-morbid conditions 
 No congenital  abnormalities39 
3.3.5. Complicated UTIs:  
 
 
               They are seen in individuals who have one or more structural and functional 
abnormalities. It may be seen in the following conditions. 
 Immunosuppression 
 Obstruction due to tumor ,Benign Prostatic Hypertrophy 
 Congenital abnormalities in the urinary tract  
 Renal calculi and renal failure 
 Renal transplantation 
 Foreign bodies (e.g., Indwelling catheters or other drainage tubes if kept ) 
 Infection in pregnant women and hospitalized patients39. 
3.4. Predisposing factors for UTI: 
3.4.1. Host factors: 
 Mutations in Toll-like receptors and the interleukin 8 receptor genes lead 
to recurrent UTI and pyelonephritis.   
 Behavioural changes- sexual activity can introduce the flora and can 
cause infection. 
 Spermicidal agents (Nonoxynol-9) can alter the vaginal flora which 
interferes with the pathogen
39
.  
 Low level of CXCR2 expression on neutrophils is prone for recurrent 
UTI
40
. 
3.4.2. Demographic factors: 
 Age- UTI may be experienced in neonatal age group, frequently seen in 
adults and reaches peak in old age group
41
.  
 Gender- Females are more affected than men due to structural and 
anatomical changes. 
3.4.3. Genetic factors:            
             The susceptibility to colonization has been linked to an increased receptivity 
for the attachment of bacteria to the epithelium, and to an overrepresentation of the P1 
blood group phenotype
39,42
. 
3.5. Routes of infection: 
Three possible routes of urinary tract infections are
43–     
 Ascending route 
 Haematogenous route  
 Lymphatic routes 
3.5.1.  Ascending route: 
                  It is the most common route where bacteria can ascend up and cause UTI. 
Mostly bacteria originating from bowel get colonized in urethra. Once it reaches the 
bladder, they can multiply and gain entry to the ureter and further invades renal 
parenchyma and pelvis.   
3.5.2. Hematogenous route: 
                  It is very uncommon in immunocompetent individuals. Because the kidney 
receives 20% to 25% of the cardiac output, any microorganism that reaches the 
bloodstream can be delivered to the kidneys.   
 
3.5.3. Lymphatic Route: 
               It is less likely to be the route of infection.  In retroperitoneal abscess, it may 
spread to the urinary tract through the lymphatic system. 
3.6. Host defense factors in the Urinary Tract:  
Table 3- Description of host factors in urinary tract and its defense mechanism
44
 
Defense factors Preventive mechanism  
1.Urinary 
 Factors 
 Urinary pH and osmolarity level- Inhibits pathogen 
 Secretion of cytokienes- Mucosal immunity  
 Tamm Harsfall protein – Prevents binding of bateria 
 Polymorphnuclear neutrophils (PMNs)-  Phagocytosis  
2.Immunological 
factors 
 Secretary IgA – prevents attachment of pathogens 
 to host epithelium and provides mucosal immunity. 
 Complement system- Antibactericidal action lytic pathway 
 Serum- Bactericidal action 
3.Physiological 
Factors  
 Micturition , Ureteric peristalsis- Flushes the bacteria  
 In men - Zinc in prostatic fluid – Bactericidal action 
4.Anatomical 
Factors    
 Longer length of urethra in males prevents  infection- 
 prevents ascension of organisms 
 
 
3.7. Clinical Manifestations: 
                             
     Fig 3: Anatomy of the urinary tract, with corresponding terms and diseases
32
.   
3.8. Terminologies in UTI: 
3.8.1. Asymptomatic bacteriuria / UTI- There is significant bacteria in the urine with or 
without any clinical signs and symptoms of UTIs which usually requires treatment. 
 in the elderly, in residents of long-term care facilities,  
 Diabetes mellitus 
 patients with a long-term indwelling Foley catheter 
 
3.8.2. Acute symptomatic UTI- Cystitis, Urethritis, Prostatitis, Pyelonephritis  
                Cystitis, Urethritis, Prostatitis- It usually manifests with dysuria, frequency, 
urgency of micturition  and  rarely suprapubic tenderness.                        
                Pyelonephritis- It manifests with the symptoms like flank pain, tenderness, or 
both, and fever, often associated with dysuria, urgency, and frequency. Rarely it  may 
complicate into renal abscess. 
3.8.3. Urosepsis – It is a sepsis syndrome usually documented in complicated UTI by 
dissemination of organism in to the bloodstream. It includes the presence of symptoms of 
UTI plus two or more of the following:  
 
 
 
 
 
 
Temperature >38° C or <36° C 
 Heart rate >90 beats/min 
Respiratory rate >20/min   
WBC >12,000cells /mm3, <4,000 cells/ mm3 
 
 
3.8.4. Single episode UTI occurs once and it does not recur.  
3.8.5. Recurrent Episode UTI refers to repeat infections with or without clinical 
manifestations  
3.8.6. Recurrences of UTI may be relapses or reinfections-  
                Relapse - refers to a recurrence of UTI with the same infecting microorganism 
which was present before therapy was started. This is caused by the persistence of the 
same organism in the urinary tract.  
                 Reinfection - It is a new infection caused by different pathogen from the 
original bacteria. 
3.9. Historical Background of laboratory diagnosis of UTI:  
                 In 1956 classic study, Kass provided clear criteria between the number of 
bacteria in the urine of asymptomatic or symptomatic females with pyelonephritis and 
those who were not infected. Since 1956, urine cultures were interpreted as per 
quantitative method and were considered  as one of simpler tests to diagnose UTIs. It was 
also clearly understood that ≥105 CFU/mL was a positive test result and indicated 
infection.  
                In 1982, Stamm and his coworkers restudied the criteria for patients with   
lower UTIs. In his study, it was found that in contrast to Kass’s work, he included the 
coliforms at a threshold above 10
2
 CFU/mL. The prevalence of infections in females was 
36% in his study whereas in Kass’s study it was only 6%. Because of this higher 
prevalence of infection, the positive predictive value (PPV) of infection was increased 
and the number of false-positivity decreased. Stamm also tried to differentiate the true 
infection from contamination. 
              Since 1980s the significance of pyuria was high, many investigators reevaluated 
and assessed the accuracy of the classical urinalysis method. Later it was also used to 
detect casts and crystals
32
. Nowadays many modern and advanced methods have been 
developed to detect pyuria and bacteriuria. 
 
  
 
 
 
                          
 Chemstrip LN 
  
 RUS, Rapid-Urine-Systemboth males  
 
 
                    Based on the numerous publications, it was clearly understood that the 
source of the majority of UTIs was patient’s endogenous flora. Many literatures were 
published and reported that E.coli was the predominant  uropathogen among the enteric 
 Macroscopy – Turbidity 
  Microscopy – pus cells, bacteria, Red blood cells (RBCs), casts and 
crystals. 
 Culture Methods – for quantification ( Semiquantitative method) 
  Rapid screening tests - Griess nitrite test, Leucocyte esterase test, 
Triphenyl tetrazolium chloride test, Glucose oxidase test, Endotoxin 
assay (Limulus assay) 
  Automated Methods- Enzymatic methods, Colorimetric Photometry,  
Flow cytometry, Bioluminescence
32
 
 
 
 
coliforms. Recent publications also proved that E.coli had been commonly encountered 
in both community and hospital. 
3.10. Common contaminants and uropathogens in the population: 
Table 4- Shows various commensals and pathogens in the urinary tract
32
 
Contaminants   Pathogens (Kidney, bladder, urethra) 
Alpha and Beta hemolytic   
streptococci  
Bacillus species  
CONS  
Diphtheroids  
Lactobacillus spp.   
E. coli  
Streptococcus spp.  
Niesseria gonorrhea  
Chlamydia trachomatis 
Enterobacteriaceae 
Enterococci spp 
Pseudomonas aeruginosa  
Staphylococcus epidermidis 
Staphylococcus saprophyticus 
Mycoplasma 
 Gardenella vaginalis  
Anaerobic bacteria  
Corynebacterium urealyticum 
Ureaplasma urealyticum  
Coagulase negative Staphylococci (CONS)  
Virus: Adenovirus 11 and 21 
Parasite: Trichomonas vaginalis, Schistosoma haematobium 
   
              The above table shows that  Enterobacteriaceae contributes a major part in UTIs. 
Among them E.coli still remains the predominant cause of UTI worldwide and has been 
extensively studied.  
3.11. Frequency of uropathogens causing UTI: 
       
 Fig:4-Uropathogens and their association with risk factors. (Adopted from Flores-
Mireles A L et al 2015)
45
 
                     The above figure depicts the commonly encountered uropathogens among 
complicated and uncomplicated UTI and also revealed that E.coli is the most common 
cause of both the complicated as well as uncomplicated UTI worldwide. Its prevalence in 
India varies from place to place. 
3.12. History of E.coli:   
              
  Many species in Enterobacteriaceae were originally described as genera Bacillus 
and Bacterium previously.    
Table 5- Historical milestones in the evolution of Escherichia and its species
46
 
Year  Scientist  Contribution  
1884 TheodorVon Escherich  Established pathogenic properties of E.coli in 
extra intestinal infections. 
1885 Theodor Von Escherich  Termed as Bacterium coli commune 
1893 Theodor Von Escherich  Postulated that it causes ascending UTI 
 in young women. 
1895 Migula  Termed as Bacillus coli  
1919 Castellani and Chalmers Renamed  Bacillus coli as E.coli 
1973 Burgees et al  Discovered E.blattae 
1982 Brenner et al Discovered E.hermanii 
1985 Farmer et al  Discovered E.ferguisoni 
2000 Thomas and Russo Discovered ExPEC 
2003 Huys et al  Postulated that E.alberti was  
associated with infantile diarrhea. 
    
 
3.13. Taxonomy:  
 
 
 
 
              
                       
3.14. Habitat of Escherichia coli:  
              E.coli is the primary and consistent inhabitant of intestinal tract in humans and 
many warm blooded animals
47
. It typically colonizes the gastrointestinal (GI) tract of the 
infants within few hours after birth and thereby the host attains benefit from E. coli
 48
. It 
is excreted in feces and survives in the environment. So it is considered as an indicator 
organism for fecal contamination and as an important parameter in food and water 
hygiene. 
3.15. Serogroups: 
                        Serotyping of E. coli is the most commonly used method to distinguish the 
pathogenic isolates from coliform E. coli. Totally, 173 O-antigens, more than 53 H-
antigens and more than 80 K antigens were found.  Serotypes causing diarrhoea are 
different from serotypes of extra intestinal infections.
 
 There are many possibilities of 
   Table.6. Taxonomical hierarchy of E.coli 
 
Domain                              Eubacteria 
Phylum                              Probacteria 
Class                                  Proteobacteria 
Order                                 Enterobacteriales 
Family                               Enterobacteriaceae 
Genus                                 Escherichia 
Species                               coli 
combinations of O: H: K antigens in causing variety of infections. Orskov et al reported 
that 06:K13:K1 strains are particularly associated with cystitis
49
. 
3.16.  Morphology of E.coli: 
                        It is a gram negative bacillus which is approximately 2-6 μm in length and 
1.1 -1.5μm in width with rounded ends. It is motile by its peritrichate flagella. It 
possesses capsule or microcapsule made up of polysaccharides. Fimbriae are filamentous 
and protinaeceous hair like appendages surrounding the cell.  
                                                
        Fig.5: Schematic picture showing components of the cell wall of E. coli
50  
 
3.17. Metabolism: 
                     It is a facultative anaerobic organism. It shows fermentative 
metabolism. 
3.18.  Cultural characteristics: 
                            Optimal growth temperature is 37⁰C and grows well in ordinary media. 
It shows uniform turbidity in liquid media. After 18-24 hours of incubation, E. coli forms 
large (2-3mm), circular, convex, and non pigmented colonies on nutrient agar, non 
hemolytic colonies on blood agar and large pink colonies on MacConkey agar. Mucoid 
nature of the colonies is due to the production of slime layer
51
.   
3.19. Role of E.coli in humans – Normal Flora 
                            E. coli and other facultative anaerobes constitute about 0.1% of gut 
flora
34
.   The niche of E. coli depends upon the nutrients available in the host intestine 
and maintains its mutual relationship with the host. It helps in absorption of vitamin K 
and other nutrients in the colon. It strictly confines to the mucosa or epithelium of 
intestine and it remains harmless
52
.
 
    
3.20. Pathology & pathogenesis of E.coli:  
                            It causes intestinal manifestations such as invasive type of diarrhoea, 
Travellers diarrhoea, hemorrhagic type,etc., by improper hygiene. It can also cause some 
extra intestinal infections like Urinary tract infections by colonisation of anterior urethra 
and causes pneumonia,meningitis,bacteremia and septicemia by dissemination. 
                                 
     Fig:6-Site of colonization of pathogenic E.coli in the host(Croxen et al., 2013)
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Abbreviation: EPEC-Enteropathogenic E.coli, ETEC-Enterotoxigenic E.coli, EAEC- 
Enteroaggregative E.coli, EIEC- Enteroinvasive E.coli, EHEC-Enterohemmorahgic 
E.coli, DAEC-Diffusely adherent E.coli, NMEC-Neonatal meningitis causing E.coli 
3.21. Uropathogenic Escherichia coli (UPEC) 
                           Although UTIs are caused by many species of microorganisms, most are 
caused by E. coli. Non-pathogenic and pathogenic E. coli which migrate from the colon 
colonizes the urinary tract and persists for a long time
13
. Hence, UTI starts with 
colonization of periurethral region which are derived from host fecal flora
44
. Genes 
coding for various urovirulence factors of E. coli are often duplicated in uropathogens 
and grouped as pathogenicity islands which are not present in coliforms
54
. These genetic 
changes enable the pathogenic E.coli to adopt and persist in the urine. Single or multiple 
genes encoding a single virulence factor is not sufficient to make the bacteria producing 
infections. All together enhances the survival of bacteria and their multiplication within 
the urinary tract.    Significant virulence factors expressed by UPEC like adhesins, 
haemolysins, siderophore production, capsular polysaccharide and outer membrane 
proteins which help to maintain the extra intestinal survival and enable it to colonize the 
urinary tract and cause UTIs. 
  3.21.1. Virulence factors (VFs) of UPEC:    
                            Virulence factors of UPEC that have been potentially implicated as 
important in establishing UTIs can be divided into two groups:  
(i) Virulence factors associated with the surface of bacterial cell and  
(ii) Virulence factors, which are secreted and exported to the site of action55. 
They have been listed and shown in table 7. 
Table 7- List of Virulence factors produced by UPEC
55
 
Surface VFs:  
 Adhesins – Fimbrial  and 
afimbrial antigens 
 Flagellum Flagella – H 
Antigen 
 Capsular polysaccharide- K 
Antigen   
 Somatic –O Antigen 
 Outer membrane proteins   
  
Exported VFs: 
 Toxin genes 
 Hemolysin     
 Cytotoxic necrotizing factor-1(CNF-1) 
 Uropathogenic-specific protein(USP) 
  Secreted autotransporter toxin (SAT) 
 Siderophore  
 Enterobactin 
 Aerobactin 
 Yersiniabactin 
  Salmochelin  
 
3.21.1.A ) Adhesion:  
                   When UTI was recognized for the first time, it was also found that isolates 
causing UTIs could typically agglutinate with human RBCs and urothelial cells.   Many 
authors observed that there was significant association between the isolate and its 
adherence and resistant to D-mannose (MRHA) 
56
. It was explained by many researchers 
that both the properties were mediated by fimbriae. Many researchers called them 
“filaments”, an unspecific term which was also used by Brinton et al. 57. The distinctive 
name, “fimbriae”, was proposed by Duguid et al. 58 in 1955 and has since been adopted 
by most authors publishing work on the subject in Britain and elsewhere. 
                        Adhesion is mediated by Fimbrial or F-antigen. It is the essential step in 
colonization of the pathogen otherwise it would have been washed out.  Studies showed 
that fimbriae is responsible for adhesion, colonization, invasion of  host epithelium and 
makes UPEC  to escape from the innate immune system by internalization process  
within  urothelial cells  which is mediated by the  transduction cascades. Once it gets 
harbored inside the vesicle, it could not be expelled out and makes it more virulent.   
3.21.1.A.i)  Mannose resistant adhesions: 
            3.21.A.ia) Type P fimbriae
53
:   
        This type of fimbriae mediates Mannose- resistant Hemeagglutination (MRHA) that 
binds specifically to few receptors on the P blood group antigens of human RBCs and 
uroepithelial cells. Pathogenic islands contain many pap genes which codes for P 
Pili(pyelonephritis-associated pili).  PapA, the major structural subunit required for the 
formation of fimbriae and has least role in adherence to galactoside moieties (Gal-Gal) is 
present on the upper urinary tract and on erythrocytes
59
. Pap G is the most important one 
and binds to Gal-Gal moiety found in the renal epithelium, and promoting the virulence 
property. Pap G tip adhesion of P fimbriae is responsible for pyelonephritis.   
 
 
3.21.1.A.i.b) Mannose sensitive adhesions/Type 1 fimbriae
57
:     
                    UPEC strains express Type 1 pili which mediates mannose sensitive 
hemeagglutination in which agglutination is inhibited by D-mannose. It binds to a 
receptor called mannosylated glycoproteins uroplakin by FimH adhesins which are 
expressed more in the tip of fimbriae
60
.  This binding of Fim H with urothelium  is 
required for colonisation. Then the activated Fim H adhesins migrate towards the deeper 
layers of epithelium. The invasion step continues as the UPEC proliferates and forms 
clusters which are the niche of biofilm foramation. Additionally, E. coli isolated from 
patients with cystitis and pyelonephritis was observed to possess different patterns of on 
and off switching of the invertible element at specific times after transurethral 
inoculation. This finding suggested that the ability to switch the expression of type 1 
fimbriae may be necessary for full virulence in the urinary tract.
 60 
 It has been studied 
that renal specific Tamm-Horsfall proteins can act as FimH receptor and prevent the 
binding of E.coli to the host epithelium and thereby the ability of colonization is 
restricted
61
. 
Others:  
3.21.1.A.i.c) S fimbriae – Binds to Sialyl-(α-2-3) galactoside residues expressed on the 
uroplakin proteins on urothelial cells
62
.  
3.21.1.A.i.d) F1C fimbriae – Role of receptor binding site is not well studied63. 
3.21.1.A.i.e) M adhesin - Binds to M blood group antigen on glycophorins. 
3.21.1.A.i.f)  G adhesin - Binds to N-acetyl glucosamine moiety   
3.21.1.A.i.g) Dr adhesin – They bind to the Dr blood group antigen (Dra) expressed on 
decay accelerating factor (DAF) of erythrocytes. DAF is a cell membrane protein and its 
role is to prevent lysis of bacteria by complement system. They are expressed by cystitis 
causing Ecoli isolates. They are either fimbriated or afimbriated
64 
  
3.21.1.A.i.h) Curli fimbriae- Made up of subunits CsgA and CsgB. It has been found 
that its role is to promote biofilm formation, adhesion and colonizatsion of perineal area
65  
3.21.1.A.i.i) Afimbrial adhesions - AfI and AfIII 
3.21.1.A.i.j) X adhesion – Unknown specificity  
3.21.1.B.  Capsular antigens / K antigen:  
                       It is capsular polysaccharide antigen which forms a thick, mucous-like, 
layer present on the envelope of few strains of E.coli.  As per the observations of Johnson 
JR, there are more than 80 different K-antigens have been recognized
105
. Of those K 
antigens in capsules K1, K5 and K12 may be expressed by strains causing neonatal 
meningitis, pyelonephritis and septicemia. 
                       The capsular antigens of E.coli acidic polysaccharides, which can be 
divided into groups (I and II) on the basis of molecular size, nature of the acidic 
component, coexpression with O antigens, and temperature regulation of their 
biosynthesis. 
66
   
 
 
 
  
  
 
 
 
                     
                Cell wall associated virulence factor called Slime factor confers the property of 
adherence capacity and survival capacity. UPEC also produces another subset of capsule 
called colanic acid which have the same role in pathogenesis of UTI. Depending on their 
genetic and biochemical nature, they may be linked to LPS
66
. Role of capsule is 
protecting the bacteria from phagocytic and   complement activity of host. And also it 
contributes resistance against bactericidal action of human serum and biofilm formation.  
3.21.1.C. Serum resistance: 
                As explained by many reporters, the bacteria are knocked off by normal serum 
by bactericidal activity through alternate complement system. It has been reported that 
the degree of serum resistance of the bacteria is proportional to the amount of capsular 
material present in that bacteria. Smooth strains are more serum resistant than rough 
strains
67
.    
 3.21.1.D. Lipopolysaccharides („O‟ Antigens)  
                       It is a lipopolysaccharide antigen or somatic O antigen. It is heat stable. 
There are about 190 different O-antigens identified and they cross-reacts with other 
Group I 
Molecular weight – more 
than 100,000 
Heat stable and acid stable 
 It is related to Klebseilla 
spp capsular antigens. 
Group II 
Molecular weight – less than 50,000 
Heat labile and acid labile 
It is identical to capsular antigens of 
Hemophillus influenzae types a & b, 
Group B Neisseria meningitidis  
serogroups of E. coli and also with other members of Enterobacteriaceae.  They are 
responsible for endotoxin production which has antiphagocytic and anticomplementary 
effect. According to Roland Stenutz and his cowokers 75 % UTIs are caused by the   O 
serotypes- O4, O6, O14, O22, O75 and O83
68
.  Manges and his coworkers  stated that 
there is no single phenotypic profile that could cause UTI  since they are found to be 
clonal
69
. 
3.21.1.E. Flagella / H Antigens:   
                       They are expressed by motile strains of E.coli. It is heat labile antigen and 
composed of a protein, flagellin. There are more than 54 H-antigenic types in E.coli 
alone. It initiates the neutrophil recruitment and proinflammatory response. O6: K2: H1: 
F7 was identified as typical strain causing pyelonephritis
49
. 
3.21.1.F. Toxins:  
3.21.1.F.i) Haemolysin:   
                It was mentioned in the study by Stephen that hemolysin was first described by 
Kayser in 1903 and Schmidt in 1909
70
. The pathogenesis of hemolytic strains in causing 
UTIs was later described by Welch and Hacker
71
. Smith was the first one who classified 
hemolysin into two types
72
-    
 Alpha haemolysin / HlyA- cell free factor   
 Beta haemolysin / HlyB - cell bound factor  
               Hilbert DW and his colleagues studied hemolysin production and proved that 
they could inhibit the cytokiene production of host cells and promote the cytotoxicity
73
.  
They are pore forming toxins seen mostly in Gram negative bacteria. It causes lysis of the 
erythrocytes which release nutrients and other vitamins available for the bacteria. At the 
same time it releases inflammatory mediators and enzymes which are cytotoxic to renal 
proximal tubular epithelial cells, RBCs and leukocytes, thereby causing renal epithelial 
damage. Hemolysin production is seen more in UPEC strains causing pyelonephritis than 
cystitis. Recently Kreft B and his coresearchers  stated that hemolysin  production may 
contribute to  renal failure
74
.    
                   The genes encoded for the production of alpha-hemolysin are either plasmid 
mediated or chromosomal mediated. They are required for the synthesis, post 
translational modification and secretion of the toxins.  
3.21.1.F.ii ) Cytotoxic necrotizing factor-1(CNF-1): 
                 Many in vitro studies reported that CNF- 1 interferes with the phagocytosis of 
E.coli by the WBCs and thus it leads to exfoliation and apoptosis of bladder epithelial 
cells. It further enhances the easy access of bacteria into the underlying tissue
75
. More 
CNF-1 is produced by isolate causing UTI than those causing diarrhea. However, the 
detailed virulence mechanism of CNF1 in invasion of upper urinary tract is not clearly 
studied. These toxins can alter signaling pathways, provoke the inflammatory response 
and prevent the apoptosis thereby they cause the UPEC population to expand. Many 
studies proved that the cytotoxicity process releases required nutrients to UPEC and 
allows it to invade the deeper part of the urinary tract
76
.      
3.21.1.F.iii) Uropathogenic-specific protein (USP Protein):  
                    It has been observed that they are more frequently associated with all 
serotypes of UPEC. The usp gene is located on the chromosome. Usp has been expressed 
in pathogenic E.coli isolated from patients with cystitis, pyelonephritis and prostatitis
77
.  
3.21.1.F.iv)  Secreted autotransporter toxin (SAT): 
                       It is mostly produced by the pyelonephritic strains of E. coli. It shows 
toxicity towards the renal epithelial cells and hence causing Upper UTI
78
.     
 3.21.1.F.v) Cytolethal distending toxin (CDT): 
                       This toxin causes DNA damage in host epithelial cells and leading to 
progressive cell distention and cell death
79
.   
 3.21.1.F.vi)  Tcp: 
                        Toll/ interleukin receptor (TIR) domain-containing protein acts as 
virulence factor by interfering with the TLR signaling pathway
80
.    
3.21.1.G) Iron acquisition system by Siderophore:        
                         Most of the studies were performed on the basis of siderophore 
production and proved that the bacteria require iron as an essential nutrient for the 
aerobic respiration. E. coli seeks iron for colonization, metabolism, multiplication and 
survival in the host environment. So virulent isolates uptake the iron from host by 
producing siderophores. Siderophores are iron complexing protein structures which help 
in maintaining the iron concentration at a higher level. It secretes the protein to the 
surface of the cell, where Fe3+ is extracted and mediated by haemagglutination or 
cytolysis process of host cells thereby iron is taken up into the pathogen through an outer 
membrane protein receptor
81
. 
         Four types of siderophhore are produced by UPEC. They are  
 Enterobactin  
 Salmochelin 
 Aerobactin  
 Yersiniabactin  
                    Among them, aerobactin is the most frequently isolated type in E.coli 
causing pyelonephritis.  It is responsible for intracellular bacterial communication on the 
superficial bladder epithelial cells. Salmochelin, a glucosylated form of enterobactin 
which represents an immune evasion strategy. Genes encoding aerobactin, salmochelin, 
and yersiniabactin receptors are found more frequently among pathogenic E.coli, while 
enterobactin type is utilized by both commensal and pathogenic E.coli strains. Some 
studies showed that increased yersiniabactin and salmochelin synthesis were detected in 
patients with recurrent UTI.  
 
 
 
3.21.1.H ) Biofilm formation:  
                   It is one of the several putative virulence factors contributed by UPEC. This 
mechanism is due to the production of slime layer by virulent strains and the presence of 
adhesins for the adhesion of microorganisms to the host epithelial cells or on the devices.  
  
Steps of biofilm formation are 
82
   
i. Attachment – irreversible process  
ii. Cell-Cell Adhesion 
iii. Matrix Component Formation  
iv. Proliferation / Maturation  
v. Detachment or Release into the host environment.  
                        
                     Fig 7 –    Steps of biofilm formation (Sara M. Soto et al83) 
                      Other factors that contribute in the formation of biofilm are flagella, 
autotransporter proteins, Type 1 fimbriae, Curli fimbriae and F- conjugative pilus. It was 
observed by Hancock that biofilm formation of UPEC is enhanced by the availability of 
iron by the host cell
84
.   
                     The cells producing biofilm get trapped into the extracellular matrix which 
can prevent them from the action of neutrophils. This became less permeable to 
antibiotics.
   
It also causes recurrent infection and antibiotic resistance if the drainage tube 
kept for longer days. So it is considered as an important Virulence factor in contributing 
to Catheter Associated Urinary Tract Infection (CAUTI) 
85
. 
3.21.2) Genes encoding the virulence factors in UPEC:  
Table: 8- List of genes coding Virulence Factors of UPEC
55
 
Virulence factors  Genes   
Adhesins 
 Type 1 fimbriae 
 
Fim A, Fim I, Fim F, Fim G, Fim H 
 Type P fimbriae  Pap G 
 Curli fimbriae  Crl 
 Afimbrial adhesions Afa 
Capsular polysaccharides KpsM 
LPS/ Somatic O antigen   rfa, rfb , rfc 
Serum resistance  colV, iss and traT 
Outer Membrane Proteins chuA, iroN, ireA, iha, iutA,  
fliC, ompA, ompC, omp X 
Cytotoxic  necrotizing factor  Cnf 
Alpha Hemolysin  HlyA, HlyB, HlyC, HlyD 
Secreted autotransporter toxin Sat 
Cytolethal distending toxin Cdt 
Toll/interleukin receptor  domain-
containing protein 
TcpC 
 
3.21.3) Summary of Pathogenesis of UTI by UPEC: 
                       The term UTI covers a variety of conditions with different causes and 
makes the survival of bacteria in the urinary tract. The severity of a UTI depends on the 
protective mechanisms of the host, the virulent property of the agent and the supporting 
environmental factors. 
              Step1:  Colonization of coliforms   
              Step2:  Invasion of E.coli 
              Step3:  Attaining virulent property 
              Step4:  Adhesion to the uroepithelial cells  
             Step5:  Lysis of the uroepithelial cells   
              Step6:  Evades immune mechanism  
              Step7: If not properly treated, dissemination from lower urinary tract to upper 
urinary tract.    
              
 
                 Fig-8: Pathogenesis of complicated and uncomplicated UTI 
(Flores- Mireles et al  2015)
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3.22. Management of UTI: 
3.22.1. Before discovery of antibiotics: 
             The origin of UTI was not recognized and no specific antimicrobial therapies 
were available so the treatment of UTI was only palliative in the preantibiotic era. 
 The Egypt (Ebers papyrus) physicians- recommended mostly the herbal 
products. 
 Roman medicine – explained the conservative approach (bed rest, diet, 
narcotics and herbs)   
 Greek physicians- introduced some invasive techniques like lithotomy for 
stones and catheterization for retention). 
 The Arabian physicians- introduced the method uroscopy. 
 In 19th century many physicians managed UTI by hospitalization, bed rest, 
diet changes, narcotics, herbal enema products and douches and with surgical procedures 
for stones, abscess and retention
87
.  
  Later various antibacterial agents like hexamine, mercurochrome were 
introduced. But their outcomes in clinical practices were not satisfactory
87
. 
3.22.2. Post antibiotic era: 
                               In the 1950s, Nitrofurantoin was first used. It was the first tolerable 
and effective drug available for the treatment of UTIs.
 
During 1970s, Amoxicillin and 
other β-lactams were introduced. Slowly the developed resistance and shifted to 
Cotrimoxazole as the drug of choice in UTI.              
                               Resistance to antibiotic agents is not a modern concept.  Penicillinase 
producing E.coli was first isolated in 1940 even before penicillin entered to the clinical 
use. Since then, patients developed resistance to third generation cephalosporins. Later 
on, extended spectrum cephalosporins   developed resistance rapidly due to the 
emergence of ESBLs
88
. ESBLs were first reported from Europe. Several sporadic cases 
and outbreaks have been reported from France in early 1980s
89
. 
           
Figure 9: Prevalance of resistance of Gram-negative uropathogens to third-
generation cephalosporins globally
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               Ranjini CY and Singh S reported that prevalence of ESBL producing E.coli 
isolates in patients with UTI was 39.66% and 36.05% respectively
91,92
.   Azim and his 
coworkers found that more than 48 h hospitalization, use of multiple antibiotics and 
presence of other co-morbid illness were associated significantly with ESBL & MBL 
producing bacterial colonization among high risk patients
93
.  Worldwide the prevalence 
of resistance varies in different places based on their affordability, the frequency of usage 
of antibiotics, duration of treatment course on every episode of UTI especially if admitted 
with any complications. Different studies showed that ESBL producing isolates 
expressed different range of sensitivity rates for other drugs such as fluoroquinolones, 
aminoglycosides, and fourth-generation cephalosporins.   
                 Maximum studies reported that UPEC is the most common pathogen isolated 
and showed resistance to more than one antibiotic.  ESBL procucers can be treated with 
Imipenem and Piperacillin-tazobactam and carbapenems.  
3.23. Prevention of UTI:   
                         Generally most of the patients experience UTI in their life time; 
especially in females. Hence, prophylactic measures are often needed only for the women 
who are suffering from recurrent infections. A prophylactic dose of antibiotic may be 
needed in case of acute UTI.  
3.24. Future scope:  
                        It was experimented with whole killed vaccine or vaccines based on single 
or multiple VF that have been used in many animal models to show that they were 
protected against the strains expressing the respective virulence factors
94
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Materials and Methods 
 
 
4.0. MATERIALS AND METHODS 
4.1.1. Design of study:  
Cross sectional analytical study   
4.1.2. Setting of study:  
Central diagnostic services, Department of Microbiology, Chennai Medical College 
Hospital and Research Centre, Irungalur, Trichy, Tamilnadu. 
4.1.3. Period of study:  
The study was conducted over a period of one year (May 2016 –   April 2017)  
4.1.4. Sample size:   
 Total number of E.coli isolated from urine samples during the study period.  
4.1.5. Inclusion criteria:   
 Specimens collected from all clinically suspected cases of UTI of all age 
groups, of both OPDs and IPDs.  
 Conditions in which asymptomatic UTI occurs. (Diabetic Mellitus, 
Pregnancy) 
 Single isolate of E.coli per patient was included in the study. 
 Urine samples collected both via naturalis and catheters. 
4.1.6. Exclusion criteria:   
 Patients on antibiotics during last one month. 
 Samples obtained from the collection bag in catheterized patients. 
 Insignificant bacteriuria. 
 Polymicrobial growth in culture. 
4.1.7. Data Collection:  
                         All data were entered in Microsoft excel spread sheet.  
4.2. Ethical committee approval:  
                         This work was carried out with Institutional Ethical committee approval.  
4.3. Collection of urine samples: 
4.3.1. Clean-Catch Midstream Urine sample:  
                        The patients were given proper instructions to collect the sample to avoid 
contamination from anterior urethra. Female patients were instructed to clean the area 
around the urethral opening and let out first few drops of urine and to collect the mid 
stream urine after holding the labia apart. 
                       The male patients  were asked to collect the midstream by retracting the 
foreskin into a sterile screw-capped, leak proof and transparent container.   
4.3.2. Catheterized sample:  
           Sample was collected from the indwelling catheters under aseptic precautions.  
The catheter tube was clamped off above the port, cleaned with 70% ethanol and the 
urine was aspirated via a sterile needle and syringe.    
4.4. Specimen Transport: 
          The collected samples were labeled, transported to the laboratory and processed 
immediately to ensure maximum recovery of the pathogen and also to minimize the 
multiplication of commensals. They were refrigerated up to 24hrs in case of any delay. 
 
4.5. Specimen Processing:  
4.5.1.  Macroscopy:  
         All the urine samples were examined macroscopically and whether they were clear 
or turbid were noted. 
4.5.2. Microscopy:  
         Wet preparation of fresh uncentrifuged urine was done by transferring a drop of 
urine to a grease free clean glass slide and a cover slip was placed over it carefully 
without letting air bubbles .The slide was examined first under the low power 10x and 
then high power 40x for the presence of pus cells (significant if  10 WBC/mm3 of 
urine), micro organisms, RBCs, casts and crystals.   
4.5.3. Isolation: 
         A semi-quantitative culture method was performed by using sterile 4.0mm 
calibrated loop delivering 0.01mL of urine. A loopful of urine sample was plated on 
Nutrient agar and Cystine-Lactose-Electrolyte Deficient (CLED) agar and incubated 
overnight at 37
0
c.  
          The number of isolated colonies was multiplied by 100 for the estimation of 
Colony Forming Units (CFU)/mL of the urine sample. As per Kass criteria, the growth 
was considered as significant if colony count is ≥105 CFU/mL  and in case of catheterized 
sample it is considered as significant when the count is ≥103 CFU/mL and insignificant if 
<10
3 CFU/mL.  
            The significant isolates were further processed for identification of E.coli. The 
wet mount findings and colony count in the culture plates were correlated with the 
patient’s clinical status like age, gender, duration of symptoms, treatment history and 
source of UTI.  
4.6. Identification:  
               E.coli was identified with the following preliminary and biochemical tests done 
by standard recommended laboratory methods
95
.  
Table: 9 – Biochemical reactions of E.coli 
Grams staining Short Gram negative bacilli 
Motility by Hanging drop 
method  
Motile 
Catalase test Positive 
Oxidase test Negative  
Nitrate reduction test  Nitrate reduced 
Indole  Produced 
Methyl red  Positive 
Voges proskeur Negative 
Simmons Citrate Not utilized 
Christensens urease Not produced 
  
 
                      The biochemical reactions were recorded and tabulated. In this study, all 
the significant UPEC isolates were screened for the virulence factors namely Hemolysin 
production, Siderophore, Gelatinase, Biofilm formation, Hemagglutination inhibition 
assay and Serum resistance property. 
4.7. Detection of virulence markers of UPEC: 
4.7.1. Hemolysin production:  
                    Hemolysin production was detected by the method adopted by 
Cavalier S.J et al
96
. The E. coli isolates were inoculated on 5% sheep blood agar and 
incubated overnight at 37°C. Presence of hemolysin was detected by the formation of 
clear zone around the colonies. 
                   Positive: Zone of hemolysis around the colony   
                   Negative: No zone of lysis.    
The findings were recorded and tabulated. 
4.7.2. Hemagglutination:  
Direct bacterial haemagglutination test was performed by slide method as per 
Vagarali et al
97
. 
Triple sugar iron Acid slant / acid butt with gas 
produced, H2S – not produced 
Mannitol Motility Medium Fermented and Motile 
                All the E.coli isolates were inoculated into 1% nutrient broth and 
incubated at 37 °C for 48 hours for full fimbriation.  The red blood cells (human 'O' blood 
group) were taken and washed three times in normal saline. Then it was made up to   3% 
suspension in fresh saline. One drop of suspension was added to a drop of   48 hours   
broth culture of E.coli on a concave slide.  Then the slide was rotated for 5 minutes at 
room temperature. Appearance of clumping was taken as positive for 
haeamagglutination. Mannose resistant hemeagglutination (MRHA) and Mannose-
sensitive haemagglutination (MSHA) property were further tested by adding a drop of D-
mannose. 
                     MRHA: Presence of haemagglutination in 2% W/V D-mannose 
                     MSHA:  Inhibition of hemagglutination in 2% W/V D-mannose  
The findings were recorded and tabulated. 
4.7.3. Serum resistance:  
                              According to Benge’s method98, all the test isolates were inoculated 
into 1% Nutrient Broth and incubated overnight at 37°C. Then they were diluted in 5 ml 
nutrient broth. The diluted suspensions were incubated at 37°C for 2hours to make it 
10
5
CFU/ml. The cultures were centrifuged (1500 g for 5 min) and the deposit was 
resuspended in 5 ml of phosphate buffered saline.  
                          Serum was taken from the healthy donors. Then equal volume of serum 
was mixed with the centrifuged suspension and incubated at 37°C for 24hours. The 
viable count was checked at 0, 1, 2 and 3 hours of incubation after plating on Nutrient 
Agar. The isolates has serum resistant property if   >90% of organisms are present after 
3hours. The isolate was considered as serum sensitive when the colony count is dropped 
down to < 1% from original. The findings were recorded and tabulated. 
4.7.4. Gelatinase test:  
                          Gelatinase production was tested by stab method as done by Hass D et 
al
99
. A heavy inoculum of the test isolates was inoculated by stabbing 4-5 times on the 
tube containing nutrient gelatin medium and incubated at 37°C for 24 hours. Then the 
tubes were removed from the incubator and placed in the refrigerator (4°C) for 15-30 
minutes.  Production of enzyme gelatinase was observed by tilting the tubes. 
             If the medium flows when the tube is tilted, it is considered as positive.   
                         If the medium does not fall by tilting the tube, it gets solidified and 
considered as negative. The findings were recorded and tabulated. 
4.7.5. Biofilm Production: 
                          Quantitative assessment of biofilm production was performed by the 
method adopted by Christensen GD et al
100
.  4 – 5 colonies from overnight culture plates 
were inoculated in a test tube holding 10ml of trypticase soy broth added with 1% 
glucose. After overnight incubation at 37°C, all tubes were decanted and washed with 
phosphate buffered saline. After that, all the tubes were dried and stained with 0.1% 
safranine. Excess stain was removed and washed with deionized water. Biofilm was 
observed once the tubes were dried.  
                           Biofilm formation was considered as positive by appreciating visible 
film lines along the sides and bottom of each tube and considered as negative when there 
was ring formation at the interface and clearing of tubes. All the tubes were observed and 
graded as
100
: 
Negative – 0   
Weak positive – 1+  
Moderate positive – 2+ 
Strong positive – 3+         
The findings were recorded and tabulated. 
4.7.6. Siderophore production assay:  
                          This test was performed by universal chrome azurol sulfonate (CAS) 
agar diffusion method as described by Schwyn et al
101
. The CAS assay detects the color 
change of CAS-Iron complex form blue to orange after chelation of the bound iron by 
siderophores. A strong ligand L (e.g., a siderophore) is added to a highly colored iron 
dye complex; when the iron ligand complex is formed, the release of the free dye is 
accompanied by a color change.                         
                         This was done by inoculation of all the test isolates in nutrient broth and 
centrifugation. Then the sediment was taken and inoculated on CAS agar plates and 
incubated at 37°C for 48h and observed for colour change
102
.  
                    Positive:  Colour change from blue to orange halo 
                    Negative: No colour change     
The findings were recorded and tabulated. 
 
4.8. Antimicrobial Susceptibility Testing: 
                          As per the CLSI 2016 guidelines
103
, Kirby Bauer disk diffusion method 
was performed to assess the susceptibility pattern of all isolates
104
. Inoculum preparation 
was done by mixing 4-5 identical colonies of E.coli from a 24-hour-old culture plate and 
the colonies were suspended in 5 ml nutrient broth. The turbidity was adjusted to 0.5 
McFarland standard (1x 10
8
 cells/ml) resulting in semi-confluent growth. Then, lawn 
culture was made evenly on the agar surface of Muller Hinton agar plate using sterile 
swab. The plate was allowed to dry for 10 minutes at room temperature by keeping the 
lid closed. The antibiotic discs were then placed on the inoculum surface at 20-25 mm   
distance between the two discs. The plates were incubated at 37°C for 24 hours.   
                      Antibiotic discs used were Ampicillin (AMP), Amoxicillin-clavunalic acid 
(AMC), Trimethoprim-Sulfamethoxazole (COT), Ciprofloxacin (CIP), Nitrofurantoin 
(NIT), Gentamycin (GEN), Amikacin (AK), Cefotaxime (CTX), Ceftriaxone (CTR), 
Ceftazidime (CAZ), Cefipime (CPM), Pipercillin-Tazobactum (PIT) and Imipenem 
(IPM) - Purchased from Himedia lab. Susceptibility testing was interpreted according to 
the criteria of the Clinical and Laboratory Standard Institute (CLSI 2016).  
                       Quality control test was performed with E. coli ATCC 25922 strain.  
                       The isolates which showed resistance to at least three or more than three 
groups of antibiotics were considered as multi drug resistant E.coli. (MDR E.coli) 
                     Zone size of all the isolates against the antibiotics were recorded and noted. 
  Table:10 -Zone  Diameter Interpretive Standards For Enterobacteriaceae (CLSI)
103
 
S. 
No 
Drug Disk 
content(μg) 
Zone size ( mm ) 
≥ Sensitive Intermediate Resistant ≤ 
1 Ampicillin (AMP) 10 17 14-16 13 
2 Amoxclav (AMC) 20/10 18 14-17 13 
3 Amikacin  (AK)  30 17 15-16 14 
4  Gentamycin (GEN) 10 15 13-14 12 
5 Ciprofloxacin (CIP) 5 21 16-20 15 
6 Nitrofurantoin(NIT) 10 17 13-16 12 
7 Trimethoprim/ 
sulfomethoxazole(COT) 
1.25/23.75 16 11-15 10 
8 Ceftriaxone(CTR) 30 23 20-22 19 
9 Cefotaxime (CTX) 30 26 23-25 22 
10 Ceftazidime (CAZ) 30 21 18-20 17 
11 Cefipime (CPM) 30 25 19-24 18 
12 Pipercillin-
Tazobactam(PIT) 
100/10 21 18-20 17 
13 Imipenem  10 23 20-22 19 
 
 
 
4.8.1. ESBL screening and detection: 
                         As per CLSI 2016 guidelines, the test isolates which  showed  an 
inhibition zone of  ≤ 27mm for cefotaxime (CTX),  ≤25mm for ceftriaxone(CTR)   and ≤ 
22mm  for  ceftazidime(CAZ)  were considered as  presumptive  ESBL producer.  
                         All these isolates were further tested for phenotypic confirmation for 
ESBL production by Double Disc Diffusion Method sas per CLSI 2016 guidelines. A 
lawn culture was made on MHA plate with the test isolate, and then Cefotaxime, 
Ceftazidime discs with and without Clavulanic acid discs were placed.  The plates were 
incubated at 37
0
c overnight. The isolates were considered as ESBL producer when zone 
of inhibition around the combination disc (CAZC/ CEC) is more than or equal to 5mm 
than the cephalosporin disc alone
103
.   The findings were recorded and noted.     
4.9. Statistical analysis:  
                          Statistical analysis was carried out using SPSS software version 16.0. 
Variables were analyzed for frequencies and percentages. Chi- square test was used as 
test of association, for which p value was calculated. Significance level was set as p value 
of 0.05.  
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Wet mount  
Urine Sample 
No pus cells                 With pus cells          Asymptomatic bacteriuria 
Isolation Significant growth 
Biochemical test to confirm the isolates 
Virulence factors detection  
1. Hemolysin production 
2. Gelatinase production  
3. Biiofilm formation 
4. Hemeagglutination inhibition assay 
5. Serum resistance property 
6. Siderophore formation 
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Antibiogram 
 Sensitive                   Resistant       
  ESBL detection  
 
 Screening method  based on zone size 
recommended by CLSI guidelines  
 CLSI Phenotypic confirmatory method  - 
Double disc diffusion method (DDDT) 
 
Multi Drug Resistance    
 
If resistant to third generation Cephalosporins If resistant to ≥3 group of 
antibiotics 
 
  
 
 
 
 
 
 
Results 
 
5.0. RESULTS 
                     The study entitled “Detection of Virulence markers of Uropathogenic 
Escherichia coli from Urinary Tract Infections and its Antimicrobial Susceptibility 
pattern” was carried out in the Department of Microbiology, Chennai medical College 
Hospital and Research centre, Tamilnadu. The observations of the present study are 
tabulated in the following pages with regard to microbiological and its clinical association. 
                       The details of the laboratory data of all samples collected from May 2016 
to April 2017 (1year) are shown in fig 10.               
                  
Fig 10: Samples received in Microbiology Laboratory from May 2016- April 2017 
                             7106 heterogenous samples were received in the microbiology 
laboratory for a period of 1 year (May 2016 – April 2017). The highest number of sample 
received was urine (1989/27.9%) followed by pus (1562/21.98%), sputum sample 
1989
(27.9%)
1562
(21.98%)
986
(13.91%)
891
(12.53%)
1299
(18.28%)
379
(5.33%)
Urine Pus Blood Body fluid Sputum Stool
Total samples , n= 7106
(1299/18.28%), blood (986/13.91%), other body fluids (89/12.53%) and stool sample 
(379/5.33%). 
 5.1. Quantification of growth in urinary isolates: 
         
                                   Fig: 11- Quantification of Uropathogens 
                                 A total of 1989 urine samples received in Microbiology laboratory 
during the study period were processed for culture and sensitivity. Of these, 676 samples 
(34%) showed significant growth, 398 (20%) showed no growth, 351   (17.64%) showed 
growth of more than two isolates and 564 (28.35%) showed insignificant colony count, 
thereby showing that the prevalence of UTI in our study was 34%. The urine samples 
showing significant bacteriruia were taken for further analysis. 
Significant 
growth
( 676)
34%  
Insignificant
growth
( 564 )  
28.35%
Multiple
growth
(351)
17.64%  
No growth
( 398)
20%
Total urine samples
(n=1989)
 5.2. Distribution of uropathogens:                      
        
 
                  Fig: 12- Pattern of bacteria isolated from urine culture                 
                              In this study, Gram negative bacilli were found to be predominant 
isolates followed by Gram positive cocci and yeasts. Among the gram negative bacilli, 
E.coli (278=41.1%) was the predominant pathogen followed by Klebsiella spp 
(97=14.34%),  Pseudomonas aeruginosa (90=13.31%), Proteus spp ( 67=9.91% ) , 
Enterobacter spp ( 24=3.55% ) , Citrobacter spp (20= 2.95%) and other Non Fermenting 
Gram Negative Bacilli  ( 11=1.62%). The Gram positive cocci were Staphylococcus 
24 (3.5%)
26 ( 3.84%)
21 (3.1%)
18 ( 2.66%)
11 ( 1.62%)
20 ( 2.95%)
24 ( 3.55%)
90 ( 13.31%)
67 ( 9.91%)
97(14.34%)
278 
(41.1%)
Candida spp
Enterococci spp
CONS
S.aureus
Other NFGNB
Citrobacter spp
Enterobacter spp
Pseudomonas aeruginosa
Proteus spp
Klebsiella spp
E.coli
n=278
NFGNB - Non fermenting Gram Negative Bacilli
CONS- Cogalusae Negative Staphylococcus
aureus (18=2.66%), Coagulase Negative Staphylococcus spp (21=3.1%) and 
Enterococcus spp (26=3.84%).  Candida spp isolated from 24 samples (3.55%). 
5.3. Gender wise distribution of  UPEC isolates:  
              
                                         Fig 13: Female: male ratio 
                    Out of 278 UPEC, the maximum number of isolates were recovered from the 
female patients (n=165, 59.35%) as compared to males (n=113, 40.64%).   
 
 
 
 
 
 
    
Males -113
(40.64%)
Females-
165
(59.35%)
n= 278
5.4. Age and gender distribution in UPEC infection:  
        
Fig14: Age and gender wise distribution of UPEC 
                      In our study, the mean age was 51.75 with a standard deviation of 18.172 
years. Among those infected, extremes of age group were seen (1 year and 86 years). The 
distribution of the isolates in relation to age and gender is provided in the Figure 14.  
                     The incidence of UTI in females was higher in the age group of 41 to 60 
years (26.25%) followed by the age group of 21 to 40 years (15.1%) and the least 
percentage (2.87%) was seen below 20 years of age group. Among the male patients, the 
highest prevalence of UTI was observed above 61 years (20.14%) and the lowest was less 
than 20 years (1.43%).  
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   5.5. Prevalence of UTI in relation to patient‟s profile: 
 
Table-11:  Patients profile in UPEC infection 
Patient profile   UPEC, N =278 
 
Patient status 
Outpatient  63 (22.66%) 
Inpatient  215 (77.33%) 
Nature of sample  Via naturalis   238 (85.61% ) 
Catheterized   40 (14.38% ) 
 
                            In the current study, it was found that maximum number of UPEC 215 
(77.33%) were isolated from hospitalized patients whereas 63 (22.66%) were from 
outpatients. 40 (14.38%) isolates of UPEC were recovered from catheterized patients 
whereas 238 (85.61%) isolates of UPEC were from non catheterized patients. 
  5.6. Distribution of cases according to clinical diagnosis: 
Table12:Percentage of distribution of UPEC in complicated   
and uncomplicated UTI 
 Clinical diagnosis    
  
Number of cases  
(n= 278) 
Percentage  
% 
Complicated UTI 122  55.75% 
Uncomplicated UTI 
              Pyelonephritis (Upper UTI)                               
Cystitis (Lower UTI) 
 
62 
94 
 
22.3% 
33.8% 
 
                  In the present study, it was found that 122 UPEC were isolated from 
complicated UTI cases. Of these, 24 UPEC were isolated from asymptomatic bacteriruia. 
Whereas 62 UPEC were isolated from acute uncomplicated pyelonephritis and 94 were 
from acute cystitis. It is given in table 12. 
5.6.1. Association of risk factors in patients with complicated urinary tract infection: 
         Table – 13: Distribution of patients with various risk factors 
Risk Factors FrequencyN=122 Percent (%) 
Catheterization 40 32.78% 
Diabetes Mellitus (DM) and DM 
associated with complications   
21 17.21% 
Urosepsis  11  9% 
Renal calculi  6 4.91% 
Renal abscess   3 2.45% 
Recurrent  urinary tract infection 12 9.83% 
Benign Prostatic Hypertrophy(BPH)  8 6.55% 
Pregnancy 11 9% 
Chronic Kidney Disease(CKD) 10 8.19% 
            
                    The above table shows the frequency of various risk factors in patients with 
UTI. Out of 278 isolates, 122 (43.8%)  UPEC were isolated from Complicated UTI. It 
was noted that indwelling catheter and Diabetes mellitus were the common risk factors 
followed by history of recurrent UTI (9.83%), urosepsis (9%), pregnancy (9%), patients 
with chronic kidney disease (8.19%) and male patients with BPH (6.55%). Only 6 
patients had UTI due to calculi (4.91%) and 3 had UTI which was complicated due to 
renal abscess (2.45%). 
 
 
 
 
  
     5.7. Screening and rate of detection of Virulence markers in UPEC: 
      
Fig 15: Frequency of Virulence markers of UPEC 
                  In the present study, among the various virulence markers detected in all 278 
UPEC, hemeagglutination was observed in highest number 166 (59.71%), followed by of 
hemolysin production in 165 isolates (59.35%), serum resistance in 163 (58.63%), 
biofilm formation in 119 (42.8%) and siderophore production in 111 isolates (39.9%). 
119
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103
37%
111
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115
41.3%
113
40.6%
112
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175
62.9%
167
60%
POSITIVE NEGATIVE n= 278
The least positivity was seen with gelatinase production which was observed in 103 
isolates (37%).   
 5.7.1. Prevalence of MRHA and MSHA E.coli among Hemagglutination positive 
isolates:   
                               
                                           Fig:16.  MSHA and MRHA ratio 
                         Among 166 Haemagglutination positive isolates, 106 (63.85%)   showed 
the presence of Type 1 fimbriae (MSHA) and 60 (36.14%) of Type P fimbriae (MRHA). 
5.7.2. Grading of biofilm formation in total biofilm producers: 
MRHA
60
36.14%
MSHA
106
63.85%
n= 166
          Table-14: Grading of biofilm 
Biofilm positive Number of isolates 
N=119(%) 
  
                             Biofilm production was assessed by the tube method. In this study it 
was observed that out of 119 biofilm positive isolates, 63 were strong biofilm producers 
and hence graded as 3+, 32 and 24 were moderate biofilm and weak biofilm producers 
and graded as 2+ and 1+ respectively. It was found that 159 isolates (42.8%) were 
negative for biofilm production. 
5.7.3. Frequency of virulence markers in UPEC isolates: 
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Strong, 3+ 63 (52.94%) 
Moderate, 2+ 32 (26.8%) 
Weak, 1+ 24 (20.1%) 
                  Fig: 17. Strains carrying the number of Virulence factors of UPEC 
                                 All the six virulence factors were positive in only 7 isolates (2.51%), 
five were detected in 32 isolates (12.58%), four in 68 (24.46%), three in 70 (25.17%), 
two in 58 (20.86%), only one virulence factor was found to be positive in 29 isolates 
(10.43%) and 11 isolates (3.95%) did not show positivity for any virulence factor.  It was 
also recorded that Multiple VFs (≥ 4) were seen in 106 isolates (38.12%). 
5.7.4.Comparison of virulence factors in complicated UTI Vs uncomplicated UTI 
Table – 15: Comparison of VF (complicated Vs uncomplicated UTI) 
Virulence Factors Complicated UTI  
N= 122 
Uncomplicated UTI 
N=156 
MRHA (60) 18(14.75) 42(26.58%) 
MSHA (106) 51(41.8%) 55(35.25%) 
Gelatinase (103) 36(29.5%) 67(42.9%) 
Serum resistance(163)  67(54.9%) 96(61.53%) 
Biofilm (119) 54(44.26%) 65(41.66%) 
Siderophore (111) 52(42.62%) 59(37.82%) 
Hemolysis (165) 73(59.8%) 92(58.97%) 
    
                                  In the present study, among complicated UTI cases hemolysin 
production (59.8%) was found to be the more common VF  followed by serum resistance 
(54.9%) and biofilm formation(44.26%), whereas in uncomplicated UTI cases, serum 
resistance was the predominant virulent factor observed in 96 isolates (61.53% ) followed 
by hemolysin production in 92 (58.97%). The difference is not statistically significant ( p 
value not < 0.0001). 
5.7.5. Comparison of   virulence factors in uncomplicated UTI (Upper UTI Vs 
Lower UTI): 
Fig:16-  Comparison of VFs (Upper UTI Vs Lower UTI) 
Virulent factors  Upper UTI (%)  
Total no = 62 
Lower UTI (%)  
Total no=94 
Hemolysin  59(95.1%) 33(35.1%) 
Siderophore 33(53.22%) 26(27.65%) 
Serum resistance 42(67.74%) 54(57.44%) 
MRHA 37(59.67%) 5(5.31%) 
MSHA 23(37%) 32(34%) 
Gelatinase 31(50%) 36(38.29%) 
Biofilm  52(83.87%) 13(13.82%) 
 
              Among all 62 Upper UTI cases it was observed that hemolysin production was 
found to be the predominant VF (95.1%) followed by biofilm formation in 52 isolates 
(83.87%) and the least observed in Upper UTI was MSHA (37%).   Among 94 E.coli 
isolates from lower UTI, maximum isolates showed serum resistance (57.44%) followed 
by gelatinase production in 36 isolates (38.29%) and hemolysin production in 33 isolates 
(35.1%). The difference is statistically significant (p value is 0.0001). 
5.9. Antimicrobial susceptibility testing of Uropathogenic E.coli isolates:  
                           Antimicrobial susceptibility pattern of all UPEC isolates were tested 
against the following antibiotic discs by Kirby Bauer disk diffusion method. The results 
were interpreted as recommended by CLSI 2016 guidelines and shown in table 17.                 
Table 17- Antimicrobial susceptibility pattern of UPEC (n=278) 
S.No Drugs  Sensitive  Intermediate    Resistance 
1.  Ampicillin (AMP) 56 (20.14%) 7(2.51%) 215(98.9%) 
2.  Amoxclav (AMC) 44(15.82%) 24(8.63%) 210(75.53%) 
3.  Gentamycin (GEN) 64(23%) 11(3.95%) 203(73%) 
4.  Amikacin (AK)  238(85.61%) 3(1%) 37(13.3%) 
5.  Nitrofurantoin (NIT)  251(90.2%) - 27(9.7%) 
6.  Ciprofloxacin (CIP) 85(30.57%) 17(6.1.5%) 176 (63.3%) 
7.  Cotrimoxazole (COT)  57 (20.5%) 20(7.19%) 201(72.3%) 
8.  Ceftriaxone (CTR) 58 (20.8%) 15 (5.3%) 205(73.74%) 
9.  Cefotaxime (CTX) 81(29.1%) - 197(70.86%) 
10.  Ceftazidime (CAZ) 87(31.29%) - 191(68.7%) 
11.  Cefipime (CPM) 225(80.9%) - 53(19%) 
12.  Piperacillin–Tazobactam(PIT) 250(89.92%) - 28(10%) 
13.  Imipenem  (IPM) 263(94.6%) - 15(5.39%) 
             In this study,the highest resistance was observed for all isolates  with Ampicillin 
(98.9%) followed by Amoxyclav (75.53%), Cotrimoxazole (72.3%), Ceftriaxone 
(73.34%)   whereas  the highest sensitivity of the isolates was observed with Imipenem 
(94.6%) followed by Nitrofurantoin (90.2%), Piperacillin – Tazobactum (89.92%) and 
Amikacin (85.61%). 
5.9.1. Frequency of ESBL and MDR producers among UPEC: 
          
Fig:18- Prevalence of ESBL and MDR producing E.coli 
Sensistive 
E.coli
11%
ESBL E.coli
68%
MDR E.coli
21%
n=278
                           In the current study, 205 UPEC showed resistance or decreased 
susceptibility to one or more of the third generation cephalosporins.  Among these, the 
resistance pattern for third generation cephalosporins was highest for Ceftriaxone 
(73.74%) followed by Cefotaxime (70.86%) and Ceftazidime (68.7%).  
                           All the 205 probable ESBL producing isolates were further tested for 
phenotypic confirmation by Double Disc Diffusion method (CLSI guidelines) of which 
those 188 isolates were confirmed as ESBL producers (68%).                           In this 
study, it was also observed that all the confirmed ESBL producing UPEC isolates were 
100% sensitive to Imipenem. 
                        It was observed that 21 were MDR positive E.coli (resistant to altleast ≥ 3 
classes of antibiotics) and also it was more seen with in-patients (86.2%) than outpatients 
(13.79%). 
5.9.2. Comparison of Antimicrobial resistant pattern of UPEC from complicated Vs 
uncomplicated UTI:  
Table: 18: Resistance pattern of complicated and uncomplicated UTI 
Drugs  Complicated (N=122) Uncomplicated (N=156) 
Ampicillin 110(90.16%) 105(67.3%) 
Amoxclav 96(78.68%) 114(73%) 
Gentamycin 101(82.7%) 102(65.38%) 
Amikacin  32(26.22%) 5(3.2%) 
Nitrofurantoin  18(14.75%) 19(12.17%) 
Ciprofloxacin  95(77.86%) 81(51.9%) 
Cotrimoxazole  99(81.1%) 102(65.38%) 
Ceftriaxone 104(85.24%) 101(64.74%) 
Cefotaxime  104(85.24%) 93(59.61%) 
Ceftazidime 99(81.14%) 92(58.97%) 
Cefipime 38(31.14%) 15(9.61%) 
Piperacillin– 
Tazobactam 
21(17.21%) 7(4.48%) 
Imipenam  15(12.29%) - 
 
                           It was shown that resistance was more commonly observed in UPEC 
with complicated UTI as compared to those suffering from uncomplicated UTI. No 
significant difference was found in the resistance pattern of UPEC from both the 
complicated and uncomplicated UTI. 
5.9.3. Association of virulence factors and Multi Drug Resistant pattern: 
                        Out of 278 isolates, 58 showed resistance to atleast three or more than 
three group of antibiotics. MDR strains of UPEC were compared with various virulence 
factors and furnished in the table 19 and is given below.  
  
  
      Table:19-  VFs in MDR and Non MDR isolates 
Virulence factors  
(VF) 
MDR positive 
isolates (58) 
MDR negative  
isolates (220) 
Biofilm( 119)  39(67.24%) 80(36.36%) 
Gelatinase(103)  25(43.1%) 78(35.45%)  
Siderophore(111)  37(63.79%) 74 (33.63%) 
Serum resistance(163)  42(72.4%) 122(55.45%)  
Hemeagglutination(166)   32(55.1%)  134(60%) 
Hemolysis(165) 47(81%) 118(3.63%) 
 
                                 In the present investigation, it was observed that 47 MDR E.coli 
isolates (81%) produced hemolysin, 42 (72.4%) isolates were serum resistant. Among the 
MDR negative UPEC isolates, hemagglutination was the predominant VF observed 
followed by serum resistance in 122 isolates (55.45%) and hemolysin production in 118 
isolates (53.63%). The difference is significant statistically (p value is 0.0001). 
                    Among 106 isolates which expressed multiple VFs (≥ 4), 41 were MDR   
E.coli isolates. 
                                         Colour plates 
 
                                         Urine analysis 
 
                                        
                          Macroscopy                                            Wet mount-  
                 Turbid                                            Pus cells and bacilli   
                                   Culture characteristics           
                          
 NA plate - Large, translucent                             CLED plate- Lactose       
fermenting 
          colonies with Significant growth                                    colonies 
Identification of E.coli 
                                                            
    
                          Biochemical test showing reactions of E.coli 
 Indole-produced,  Methyl red- Positive,  Voges Prousker- Negative,  
 Simmons citrate(SC)-Utilised, Christensens Urease(CU)-not 
produced, 
 Triple sugar iron agar slant- Acid slant/ acid butt with Gas,no H2S,  
 Mannitol Motility Medium- Fermented and motile 
 
  
Virulence factors detection by phenotypic methods 
  
             
Sheep Blood agar plate- Hemolysis           Chrome azurol sulfonate agar                 
around each colony                     plate-  siderophore production(orange            
halo) 
                         
                  Nutrient gelatin agar tube- Gelatinase positive and negative 
 
           
       Serum sensitive - growth seen at 0hr, 1hr, 2hrs and 3hrs of 
incubation. 
       Serum resistant – Growth seen only at 0 hrs of incubation. 
    
  Biofilm by Tube method                Haemeagglutination- Slide method 
              Negative,1 +,2+3+                                 MRHA and MSHA 
 
          Antibiogram ( Kirby Bauer Disk Diffusion Method) 
                                   
                      Muller Hinton Agar Plate showing zone of inhibition of E.coli   
 
ESBL detection 
                                     
        Screening test- resistance to third            Phenotypic confirmatory test (CLSI- 
              generation cephalosporins                 Double Disc Diffusion Test)- shows 
                                                         zone more than 5mm in combination disc  
                                                                                                                                                                                                                                                                                           
  
 
 
 
 
 
 
Discussion 
 
6.0. DISCUSSION 
                              UPEC is the most important group of pathogens causing UTIs. Many 
molecular studies proved that urovirulent E.coli expresses many cell surface factors and 
secretes toxins and enzymes, among them few are peculiar in causing UTIs. Considering 
high morbidity and mortality rate of UTIs due to the spread of resistant and virulent 
strains among the community and in the hospital, UPEC should be focused and paid more 
attention. These virulence factors are expressed in different frequencies in different 
states
105
. Phenotypic characteristics of UPEC isolates and their correlation with antibiotic 
resistance patterns in patients with UTI are not well known. 
                             Hence, the present study was undertaken to determine the expression of 
virulence markers of UPEC and also to find out their antimicrobial susceptibility pattern.      
                            A total of 1989 urine samples were received for culture and antibiogram 
during the study period.  Urine culture positivity rate predicts the prevalence of UTI and 
was 34%. It shows similarity with other studies which showed that prevalence of UTI 
was 22.78%, 38%, 42% and 54% in other studies done by Kasi Murugan et al, Ritu 
Aggarawal et al., Nirajkumas Biswas et al. and Devanand Prakash et al, respectively 
106,107,108,109
. 
 
6.1. Prevalence of UPEC identified in  urine samples:    
                              UPEC was the predominant uropathogen isolated in our study and it is 
compared with other studies and is furnished in the following table 20.  
    Table 20: Prevalence of E.coli from UTI in different studies 
Other studies Prevalence of  UPEC 
Shamataj Razak et al
110
 37.95% 
Gupta et al
111
 42.8% 
Mekki et al
112
 49% 
Roshni Patel   et al
113
 51.8%   
M.Akram et al
114
 61% 
   
                               The second most common uropathogen was Klebsiella spp (14.34%). 
followed by Pseudomonas aeruginosa (13.31%), Proteus spp (9.91%) and other 
Enterobactericeae. It is strongly supported by the study done in Pattukkottai area in 
Tamilnadu by Manikandan C et al. in which the second most common uropathogen was  
Klebsiella pneumoniae (11.2%) followed by  Pseudomonas aeruginosa (10.5%) and  
Proteus spp., (6.8%)
115
. It is in contrast with the results of study done by Shanthi J et al in 
which UPEC (50%) was followed by Citrobacter spp., (14%) and Pseudomonas 
aeruginosa (20%)
116
. Maripandi Arjunan et al showed that UPEC (31%) was followed by 
Citrobacter spp., (20%) and Pseudomonas aeruginosa (17.24%) 
117
. 
6.2. Gender wise distribution: 
                           Our study showed that the prevalence of UTI in females (59.35%) was 
higher than males (40.4%). It strongly correlates with other findings which revealed that 
the frequency of UTI is greater in females as compared to males. Manikandan C et al and 
Kasi Murugan et al observed a prevalence of 69.8% and 52.10% in females when 
compared to 30.2% and 47.9% in males respectively.
115,106
. The reason behind this high 
prevalence of UTI in females is shorter urethra, due to its close proximity to anus, sexual 
intercourse, incontinence and other comorbid condition. 
6.3 Age and Gender wise analysis: 
                          In the present investigation, UPEC was the most frequent pathogen seen 
in both the genders and also in all age groups. Incidence is high in females in the age 
group of 41 to 60 years (26.25%) due to comorbid conditions like Diabetes mellitus, 
catheterization and incontinence and also due to alteration of normal vaginal flora in 
older age. Kalal et al observed that 31.7% of females were affected in the age group of 
15- 59 years 
118
. The study Savitha T and Bhowmick et al observations are similar to our 
study and proved that UTI is more common in older age group (41- 50 years)
119,120
. 
Further Nicolle et al stated that asymptomatic UTI is extremely common in older age
121
. 
Irene Eriksson et al reported that UTI is common in older age due to associated risk 
factors such as urinary incontinence etc., 
122        
                       Males above 61 years (19.25%) were found to be affected in the present 
study. it is strongly supported by the study Devanand Prakash et al where 30.30% of 
males were affected after 48 years and also justified the reasons for higher incidence of 
UTI in the elderly males that could be due to BPH, incontinence and neurogenic 
bladder
123
.      
 
6.4. Patients profile UPEC infection: 
                       Mostly inpatients (77.33%) were affected in the present study which is in 
contrast to the study Dehbanipour R who observed more of outpatients (67.4%) were 
infected
124
. 32.78% of UPEC patients were catheterized in this study wheeas study 
performed by Niranjan V et al showed only 13.6% of UPEC infections were 
catheterized
125
. 
6.5. Distribution of UPEC among complicated and uncomplicated UTI: 
                        In our study it was found that 55.75% and 56.1% of patients had 
complicated and uncomplicated UTI respectively whereas in the study carried out by 
Desai et al  it was 22% had complicated and 78% had uncomplicated UTI
126
 . 
6.6. Association of UPEC with various risk factors in complicated UTI: 
                        In our study catheterization (32.78%) was the most common risk factor of 
complicated UTI in UPEC infection followed by DM and associated illness (17.21%) 
whereas in Shruthi S et al where 48.38% were catheterized among the complicated 
UTIs
127
.  
 6.7. Frequency of expression of virulence factors of UPEC isolates: 
6.7.1. Biofilm production: 
                         In our study, it was observed that 52.94% of UPEC produced strong 
biofilm whereas in the study done by Poovendran Ponnusamy et al (88.2%) produced 
strong biofilm
128
. It is contrary to the study performed by Tabasi M et al where only 
17.3% were strong biofilm producers
129
.   
                         Biofilm production is always considered as serious problem in case of 
patients with indwelling catheter as it accelerates difficulty in management and antibiotic 
resistance. In this study also, it has been found that 31 out of 40 UPEC isolates among 
catheterized samples showed biofilm formation. Of these, 26 (83.87%) were found to be 
strong biofilm producers. It is discordant with the study by Makled et al in which similar 
to results in which 3% of isolates of UPEC from catheterized samples produced strong 
biofilm 
130
. 
6.7.2. Hemolysin production: 
                            In the present study, it was observed that 59.3% of isolates produced 
hemolysin. The prevalence of hemolysin production in most of the studies from India 
which is similar to the current data.  Naveen et al, Seigfried et al., and Raksha et al had 
reported that 40.7% , 59.6%, and 41.36% of isolates expressed  hemolysin production 
respectively
131,132,133
. Many authors reported that hemolysin production is associated with 
severe form of UTI by colonization of virulent UPEC since it is toxic to urothelial cells, 
causes inflammation and enters into the blood stream. 
6.7.3. Siderophore production: 
                            Siderophore production was seen in 119 (88%) isolates in this study. It 
is similar to the results of other studies performed by Mittal et al, Santo E et al and 
Vagarali et al who showed that 88%, 76% and 98% isolates produced siderophore 
respectively 
134,135,136
. Most of the researchers suggested that siderophore production 
always helps in the growth of pathogen and maintains its survival inside the host in the 
limited iron concentrations and thus acts as an important virulence marker in the 
pathogenesis of UTI. 
6.7.4. Hemeagglutination 
                             Fimbriae are responsible for adherence by pathogenic organisms to the 
host epithelial cells. Thus, MRHA property of UPEC is considered as an important 
virulence factor in UTI. Wullt B reported that Type P fimbriae was expressed by 40-60 % 
of UPEC and associated with MRHA which is similar to the present study (59.7%) 
137
.  It 
did not correlate with the study performed by Seigfried et al in which only 23% of 
isolates were positive for MRHA
128
. 
6.7.5. Serum resistance: 
                            In the current study, 58.63% of isolates showed resistance to serum 
bactericidal action. It shows similarity with the study conducted by Kauser et al in which 
49.5% of UPEC isolates showed serum resistance 
138
. It is disconcordant with Sharma et 
al where maximum (86.8%) were serum resistant. Hughes et al stated that high degree of 
serum resistance is correlated with increased virulent property of bacteria. 
139,140 
 
 6.7.6. Gelatinase production:  
                       Gelatinase production by UPEC was least studied. The present study 
showed that only 37% UPEC isolates produced gelatinase. It is in contrast to the studies 
done by Sharma et al where only 6.9% isolates produced gelatinase. 
139
           
                       Based on the observations of the present study, prevelance of 
Hemeagglutination was high followed by Hemolysin production and serum resistance 
property. The least virulence factor found was gelatiniase production. It is very similar to 
study done by Sneha Sharad et al where HA was 28.5% showed presence of 
haemagglutinating fimbriae followed by hemolytic pattern was seen in 25.5% 
141
. and 
also similar to the work done by  Tabasi M et al in which 85.3% of isolates produced 
biofilm followed by Type 1 and P  fimbriae expression (MSHA- 62.8% , MRHA- 37.2%)  
and hemolysin production in 34% isolates
129
. The results of this study did not correlate 
with Mittal et al where the most common virulence factor was siderophore production 
(88%)  followed by others in the same order
134
. 
6.8. Frequency of occurrence of virulence markers in UPEC: 
                         In the present study106 isolates (38.1%) isolates showed Multiple 
Virulence Factors MVFs (>4). It is supported by the study by Sharma S et al in which 
44% of isolates were positive for MVFs
139
.  It is not concurrent with the study Kausar et 
al who reported that 80% of UPEC expressed MVFs
139
. Zaki and Elewa reported that 
numerous virulence factors contribute to the pathogenicity of E. coli in UTI
142
.  
6.9. Comparison of VF with Complicated and Uncomplicated UTI: 
                         Among complicated UTI cases, hemolysin production (59.8%) was more 
commonly observed followed by serum resistance property (54.9%) whereas in 
uncomplicated UTI, serum resistance property (61.53%) was found dominant followed 
by hemolytic property (58.97%). It is in contrast to the study by Desai et al where 31.8% 
were serum resistant and 18.2% expressed Type P fimbriae in complicated UTI and a 
maximum of 65% showed hemolysis and 57% were serum resistant in uncomplicated 
UTI
126
.  Relationship of these virulence factors with the host factors was also studied in 
the present study by including E.coli isolates from complicated and uncomplicated UTI. 
It was found that isolates from uncomplicated UTI were multivirulent. It is supported by 
the study conducted by Desai S et al
126
 whereas in Swaroop Sai et al it was observed that 
UPEC from complicated UTI were more associated with multiple virulence factors
143
. 
6.10. Association of VF of UPEC with Upper and Lower UTI: 
                            In upper UTI, hemolysin production was more commonly detected 
(95.1%) whereas in lower UTI serum bactericidal activity was maximum (57.4%). It 
shows similarity with observations of Desai et al where hemolysis was predominant in 
both Upper and Lower UTI
126
.  
                      It had been observed that pyelonephritis cases were more associated with 
multiple virulence factors when compared   lower UTIs which is similar to Swaroop Sai 
P et al
143
. 
6.11. Antimicrobial susceptibility testing of UPEC: 
                              In the present study, highest percentage of resistance was observed 
with Ampicillin (98.9%) followed by Amoxicillin – clavulanate (75.53%) Ceftriaxone 
(73.74%) Gentamycin (73%) and Cotrimoxazole (72.3%) The resistance pattern varies 
from place to place. It is similar to the study conducted by Mohammad Reza Shakibaie et 
al and the results suggested that E. coli was extremely resistant to Ampicillin (100%). He 
also observed a resistance of 68.3% to amoxicillin/clavulanic acid, 33% to 
Cotrimoxazole. 
144
. 
                              He also stated that among Aminoglycosides, Gentamycin 
susceptibility (8.3%) was less than Amikacin (94.4%). It is similar to our study where it 
was observed that susceptibility to Gentamycin is only 23% but to Amikacin it is  85.61% 
susceptible. Cotrimoxazole showed a sensitivity of 20.5% in present study. But it was not 
in agreement with the study done by Abdul Rahaman Shariff V A et al. where he showed 
that 41.6% was sensitive to Cotrimoxazole
145
.   
                             Emergence of the resistance to the fluoroquinolones is very high. 
63.3% were resistant to Ciprofloxacin in the current study. Its prevalence in Bangladesh 
was about 26%.  Shanthi J et al also found increased resistance of ciprofloxacin in 
UPEC
146
. It is contrast to the study of Shahandashti E F et al who showed 78.9% were 
sensitive to Ciprofloxacin
147
.                  
6.11.1. Prevalence of ESBL producing E.coli in UTI: 
                            ESBL producing E.coli in UTI began to be reported in many countries 
like USA, Saudi Arabia, Nepal, Japan, China, Brazil and India
148
. It clearly shows the 
prevalence of ESBL producing E.coli in UTI in many places and also varies from place to 
place.  Previously many studies from India have reported ESBL production in UPEC 
varying from 28% to 84%
149
. Among the third generation cephalosporins, Ceftriaxone 
resistance was high (73.74%) in our study. It is similar to the study by Dandapany et al 
who also reported high resistance 87.7% with Ceftriaxone and Cefotaxime and 73.2% 
with Ceftazidime respectively
150
. Khakhkhar VM also reported 81% of isolates were 
ESBL producers and it might be due to the higher usage of third generation 
cephalosporins
151
. It is discordant with the results of Rajan S et al, Baby Padmini S et al 
where only 40% and 41% produced ESBL.
152,153
. 
                            This is a notification that most of the organisms are now ESBL 
producers. The other valid reason behind this problem is that the empirical treatment of 
UTI with third generation cephalosporins. Most of the higher drugs are still susceptible in 
many places and may be less used unless when the patient is hospitalized or admitted in 
ICUs. The sensitivity of E.coli to Imipenem (94.6%) and Piperacillin-Tazobactam was 
(89.92%). It is similar to the results of many studies. But it is dissimilar to the study done 
by Ponnusamykonar Poovendran et al where only 11% of UPEC were sensitive to 
Piperacillin/Tazobactam but Imipenem was found 100% sensitive
128
. It is similar to the 
study done by Ravindranath Gangane et al where all ESBL E.coli were 100% sensitive to 
Imipenem
154
. 
6.11.2.. Prevalence of MDR strains of UPEC: 
                             MDR pattern was observed in 58 isolates of E.coli (21%) whereas in 
study by Hasan et al in a tertiary care Indian hospital where the prevalence of MDR 
E.coli was about 52.9%.
155
 In study done by Niranjan V and his coworkers observed that 
76.5% of UPEC were MDR and also reported that they were more seen with inpatients 
(80.2%) which is similar to our study (86.2%)
125
. Mathai et al in southern India showed 
that 8.4% commensals showed MDR pattern E.coli
156
.
 
The inappropriate usage of broad 
spectrum antibiotics, poor hygiene, immunosuppressant stage and a longer stay in the 
hospital are some major factors that can increase the chances of MDR infections. It was 
observed that MDR isolates were more seen in inpatients.  
6.12.Comparison of resistance of UPEC isolates with Complicated and 
uncomplicated UTI: 
                            In our study it was found that resistance to various antibiotics was 
common in complicated UTI than those who had uncomplicated UTI. It is supported by 
the study conducted by Johnson J R
105 
et al who also reported most of the antibiotics were 
resistant in patients with complicated UTI than those suffering from uncomplicated UTI. 
6.13. Association of virulence factors with MDR E coli isolates: 
                           The incidence of multiple virulence factors in UPEC establishes the 
uropathogenicity of urinary tract. In the present study multiple virulence factors (>4) 
were present in 106 isolates (38.12%) and they had strong correlation with MDR pattern. 
It is supported with the observation of studies by Sharma S et al and Desai S et al where 
44%and 52% of UPEC expressed Multi Virulent factors 
139,126
. It was also proved that 
they showed strong correlation with MDR pattern in those studies. It is contrary with 
results of Mittal et al where a maximum of 78.5% were positive for four or more than 
four virulence factors
134
.  
                            In this study it was found that Hemolysis pattern (81%) was frequently 
observed followed by Serum resistance property (72.4%) in MDR strains of E.coli. It is 
contrast to the study conducted by Mittal et al who reported that serum resistance was 
found in 27.7% of isolates followed by hemolysin production in 23.3%.
134  
Suggestions:  
                            Further studies are suggested to find out the association between 
virulence factor production, the clinical course as well as the therapeutic response.   Since 
resistant E.coli is the emerging uropathogen found everywhere, it is suggested that the 
clinician must interact with the microbiologists regarding the choice of antibiotics. 
Though it is still common, no vaccines have not been developed yet. There is a very long 
way to go in the development of vaccines against UPEC.  So the following suggestions 
can be followed to prevent the resistance.  
 The initial choice of empiric treatment should be based on Gram stain, urine 
culture and antibiogram.  
 It is very essential to report ESBL production along with the routine sensitivity 
reporting in the clinical lab, which helps the clinicians in prescribing proper 
antibiotics or to change the antibiotics. 
 Treatment with broad spectrum antibiotics i.e. quinolones, aminoglycosides and 
3rd generation cephalosporins should be avoided in ESBL endemic region. 
 All clinicians aimed at avoiding over prescription of antibiotics should be 
implemented.  
 Good infection control measures and barrier precautions are necessary to prevent 
the spread of resistant strains.  
 Indwelling medical devices favor colonization of nosocomial pathogens. Hence, 
judicious use of catheters along with better nursing care of patients with 
indwelling devices is recommended to reduce the colonization and infection.   
 
 
 
  
 
 
 
 
 
 
Summary  
 
7.0. SUMMARY 
                              UTIs are gaining importance in clinical practice for various reasons. 
Among the causative agents, UPEC are frequently encountered. Hence the present study 
was undertaken. 
                             This study entitled “Detection of Virulence markers of 
Uropathogenic Escherichia coli from Urinary Tract Infections and its Antimicrobial 
Susceptibility pattern” was carried out in the Department of Microbiology, Chennai 
Medical College Hospital and Research Centre, Trichy from May 2016 to April 2017. 
 During the study period, a total of 7106 clinical samples were received, out of 
which 1989 (27.9%) were urine samples. Of these, significant growth was 
observed in 676 isolates (34%) which determines the prevalence of UTI. 
 The most common organism causing UTI was found to be UPEC (41.1%).  
 In our study it was observed that both extremes of age were affected with the 
mean age 51.75 years. 
 Males were more affected with UTI after 60 years of age. 
 Females were more affected in the age group of 41-60 years. 
 In this study, females (59.35% ) were more commonly affected than  males 
(40.64%). 
 UPEC were more commonly isolated from inpatients (77.33%) than outpatients 
(22.66%). 
 UPEC were more commonly isolated in patients with uncomplicated UTI (156) 
than complicated UTI (122). 
 Among the complicated UTI, patients with indwelling catheter were found to be at 
high risk (32.78%) followed by Diabetes mellitus (17.21%). 
 Acute cystitis (33.8%) were frequently encountered in  uncomplicated UTI than 
acute pyelonephritis (22.3%). 
 Hemeagglutination (59.7%) was found predominantly among various virulence 
factors, hemolysin production in 165 isolates (59.35%), serum resistance in 163 
(58.63%), biofilm positivity in 119 (42.8%) , siderophore production in 111 
isolates (39.9%) and gelatinase in 103 isolates (37%) in the above order.  
 Of these HA positive isolates, Mannose Sensitive Hemeagglutination (63.85%) 
were more common than Mannose resistant Hemeagglutination (36.14%). 
 Multiple VFs (more than 4) were seen in 106 isolates. 
 Hemolysin production was more frequently observed among patients with 
complicated UTI than with uncomplicated UTI.  
 Hemolysin production was seen in maximum isolates of UPEC from Upper UTI 
(95.1%), whereas serum resistance was maximum in Lower UTI (35.1%). 
  Highest sensitivity was observed with Imipenem (94.6%), Nitrofurantoin 
(90.2%), Pipercillin- Tazobactam (89.9%) and Amikacin (85.6%) in the following 
order. 
 The highest resistance of UPEC was observed with Ampicillin (98.9%), 
Amoxyclav (75.53%) and Cotrimoxazole (72.3%) in the above order. 
  Prevalence of ESBL producing E.coli isolates was 68%. 
 58 isolates of UPEC showed resistance to three or more than three antibiotics 
(MDR strains). 
 Among the 58 MDR E.coli, 50 (86.2%) were isolated from in-patients. 
 Comparing the virulence factors with the drug resistant pattern. It was observed 
that 58 MDR E.coli isolates showed maximum positivity (81%)   for hemolysin 
production. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Conclusion 
 
 
 8.0. CONCLUSION 
             Amongst various infections in humans, Urinary tract infections (UTIs) are 
the most common bacterial infections. 
 Of the 1989 urine samples received in Microbiology Laboratory, 676 showed 
significant growth. Of these 278 was belonged to E.coli (UPEC).  
 The prevalence of UTI was 59.35% in females and 40.64% in males. 
 In both patients with complicated and uncomplicated UTIs E.coli was the most 
commonly encountered organism. 
 When these 278 isolates of E.coli were subjected to detect these various virulence 
factors like i) hemolysin production ii) siderpohore production iii) biofilm 
formation iv) gelatinase production v) MRHA property and vi) serum resistance 
property.  Of these, 166 (59.7%) showed Hemeagglutination, 165 (59.35%) 
produced hemolysin, 163 (58.63%) showed serum resistance property, 119 
(42.8%) were biofilm positive, 111 (39.9%) produced siderophore and 103 (37%) 
produced gelatinase in the above order.  
 106 isolates (38.12%) expressed Multiple VFs (≥ 4). 
 Hemolysin production (59.8%) was the most frequently identified virulence factor 
in complicated UTI and serum resistance (61.53%) was found to be more common 
in uncomplicated UTIs. 
 Hemolysis (95.1%) was more frequent in Upper UTI whereas serum resistance 
57.44% was common in Lower UTI. 
 Highest resistance of UPEC was seen with Ampicillin (98.9%) followed by 
Amoxyclav (75.53%), Ceftriaxone (73.74%) and Gentamycin (73%), maximum 
sensitivity was found with Imipenem (94.6%) followed by Piperacillin-
Tazobactam (89.92%). 
 Prevalence of ESBL and MDR E.coli isolates were 68% and 21% respectively. 
 Most of MDR E.coli isolates (50) were from in-patients (82.6%). 
 All ESBL isolates were 100% sensitive to Imipenem. 
 Overall UPEC isolated from patients with complicated UTIs showed more 
resistance than uncomplicated UTI cases. 
 Isolates carried MVFs showed MDR pattern. 
 
 
 
 
 
 
 
 
 
 
 
 
Strengths of the study:  
 Good laboratory practices were adopted at all levels viz., sample collection and 
processing, isolation and identification, speciation and antimicrobial testing.  
 The works were monitored by all senior faculty members independently.  
 Standard media and chemicals were purchased for lab works.   
Limitations of the study:  
 It is a single center study.  
 Genotyping method was not carried out for the detection of virulence factors of 
UPEC.  
  Other antibiotic resistance mechanism like ampC detection was not performed. 
 Resistance pattern was not confirmed by molecular studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 ஒப்புதல் கடிதம் 
 
஧ங்கே஫்஧ா஭பி஦் ப஧னப:் 
 
ஆபான்சச்ிம௃஦் தல஬஧்பு: 
 
                   இ஥்த ஆபான்சச்ிலன஧் ஧஫்றின அல஦த்து விவபங்ேளுந் எ஦ே்கு 
எழுத்து மூ஬நாேவுந் வான் பநாழினாேவுந் எ஦து தான் பநாழிம௃஬் 
விவபிே்ே஧்஧ட்டது. இவ்வாபான்சச்ிலன஧் ஧஫்றி முழுலநனாே஧் 
புபி஥்துபோண்கட஦். இவ்வாபான்சச்ிலன஧் ஧஫்றின   கே஭்விேல஭ எழு஧்஧ 
எ஦ே்கு வான்஧்பு போடுே்ே஧்஧ட்டது. இவ்வாபான்சச்ிம௃஬் ஥ா஦் 
஧ங்குப஧றுவது எ஦து பசா஥்த விய௃஧்஧த்லத ப஧ாறுத்தது எ஦்றுந், இ஥்த 
(சிறு஥ீப)் கசாதல஦ே்கு ஥ா஦் முழுதுந் சந்நதிே்கிக஫஦் எ஦்றுந் 
உறுதின஭ிே்கிக஫஦்.  இத஫்கு ஥ா஦் எ஥்த வித தலடயுந் இலடயூறுந் 
பசன்னநாட்கட஦் எ஦்று சுன஥ில஦வுட஦் 
உறுதின஭ிே்கிக஫஦். இவ்வாபான்சச்ிே்கு எ஦்ல஦ உட்஧டுத்த ஧ணந் 
எதுவுந் ப஧஫வி஬்ல஬ எ஦்றுந் உறுதின஭ிே்கிக஫஦் 
 
 
஧ங்கே஫்஧ா஭ப ்லேபனா஧்஧ந்:                 
கததி: 
 
 
 
 
 
CHENNAI MEDICAL COLLEGE HOSPITAL & RESEARCH CENTRE 
“DETECTION OF VIRULENCE MARKERS OF UROPATHOGENIC 
E.COLI FROM URINARY TRACT INFECTIONS AND ITS 
ANTIMICROBIAL SUSCEPTIBILITY PATTERN” 
Name of the patient:                                                                     IP/OP No:  
Age /sex:                                                                                       Dept/ward:  
Symptoms: Fever ± chills/ Burning micturition / Frequency of urination /Loin pain  
Diagnosis: 
Pre disposing factors:  Pregnancy/DM/ Reccurent History/CKD/BPH/ Calculi. 
Treatment history: Antibiotics (Taken / not) 
Any Urological interventions done: 
Hospital stay: D.O.A-                                                                    D.O.D-  
Patient outcome: Improved/Cured/Expired/AMA  
Sample: Naturalis sample / Catheterised 
LAB DETAILS: 
Urine analysis: 
 
 
 
Culture: 
Nutrient agar plate-                                                (Significant / Insignificant) 
CLED agar plate- 
 
Macroscopy Microscopy(Wet mount) 
Clear/ Turbid Pus cells,bacilli, RBCs,Casts- Present /Absent 
Biochemical reactions: 
Indole MR VP Citrate Urease TSI MMM 
       
Virulence factors detection: 
S.n VF Result  s.n VF Result  
1. Hemolysis   4. Serum resistance   
2. Biofilm   5. Haemagglutination  
3. Siderophore  6. Gelatinase   
 
Antibiogram: 
S.no Drugs ZOI S.no Drugs ZOI 
1. Ampicillin (AMP)  8 Ceftriaxone(CTR)  
2 Amoxclav (AMC)  9 Cefotaxime (CTX)  
3 Amikacin  (AK)   10 Ceftazidime (CAZ)  
4 Gentamycin (GEN)  11 Cefipime (CPM)   
5 Ciprofloxacin (CIP)  12 Piptaz(PIT)  
6 Nitrofurantoin(NIT)  13 Imipenem   
7 Cotrimoxazole(COT)     
 
ESBL detection- (CLSI Phenotypic confirmatory test) -  Yes/No 
 
MDR- Yes/No 
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1 75 M IP 216739 C N N P N P N P R R S R R S R R R R R S S 
2 59 F IP 217536 C N N N P P N N R R S R R S R R R R R S S 
3 80 F IP 215794 C C P P P P P P R S S R R R R R R R S R R 
4 26 F IP 217713 U N N P P P P N R R S S R S R S S S S S S 
5 70 F IP 217170 C N N P N N N P R R I R R S I R R R S S S 
6 56 F IP 231586 U N N N N N N N S R R R R S R S R R S S S 
7 58 F IP 217861 U N P P P N P P R R S R I S R S R R S S S 
8 20 F IP 218254 C N N P N N N P S S S R R S R S S S S S S 
9 63 M OP 131747 U N P N N P P P R R S I R S R S R S S S S 
10 74 F IP 218317 C N N P P N P P R S R R R R R R R R R R S 
11 67 M IP 218269 C C P P N P N P R R S S R S R R R S S S S 
12 41 M IP 218276 C N N N P N N N R R S R R S R R R R S S S 
13 57 M IP 218186 U N N P N P P P R R S S R S R R R R S S S 
14 60 F IP 218195 C N P P N N P N R S R R R S R R R R R R S 
15 35 F IP 218376 U N P P N N P P R R S S S S R S S R S S S 
16 57 M IP 218506 U N N P P P N P R S R R R S R R R R S R S 
17 54 M IP 218475 U N N N N N N N R R S S S S R R R R S S S 
18 75 M IP 218726 C N N N P N N N R S R R R S R R R R S S S 
19 59 F OP 157348 C N N P N N N N S R S R S S S S S S S S S 
20 65 F OP 156421 C N N N P N N P R S S R I S R R R R S S S 
  
21 45 F IP 219120 U N P P N P P P S S S S S S R S S S S S S 
22 70 F IP 219602 C C N P N N N P R R R R R S R R R R R R R 
23 54 M IP 219149 U N P P P P P P R R S S S S R S S S S S S 
24 75 F IP 218993 C N P N N N N P R S S R R S S S R R S R S 
25 74 M OP 157176 C N N N P N N N R S S R R S S R R R S R S 
26 33 F IP 218819 U N N P N P P P S R S R R S S S S S S S S 
27 24 F OP 157213 C N N N P N N P S S S S S S R S S S S S S 
28 55 F IP 220221 U N P N P P P N S R S R R S S R S S S S S 
29 55 M IP 220144 U N P N P P P N R R S R R S R R R R S S S 
30 75 M IP 220116 C N N N N N N N R R S R R S R R R R S S S 
31 70 F IP 220208 C C P N P N P N R R R R R S S R R R S R R 
32 63 M IP 220264 U N P P N P N N R R S R R S R R R R S R S 
33 49 M IP 220278 U N P P N P N N R R S S R S R R R R S R S 
34 62 M IP 220544 U N P P N P P P R R S R R S R R R R S S S 
35 45 F IP 220740 U N N P P N P P S S S S R S R S S S S S S 
36 70 F IP 220716 C N P P N P N P R S R R R R R R R R S S S 
37 48 F IP 220696 U N N P N P P P S R S S R R R R R R S R S 
38 62 F IP 221051 C N P N P N P P R R S R R S R R R R S S S 
39 62 M IP 221023 C N N N P N N P R R R R R S R R R R S S S 
40 52 M IP 221122 C N N N P N P N R S R R R S R R R R R S S 
41 56 F IP 221220 U N N N N P P P R R S R R R R S R R S S S 
42 69 F IP 221320 C N N P P N P N R S S R R S R R R R S R S 
43 55 F IP 221416 C N N N N N N N R R S R R S R R R R S S S 
44 50 F IP 220980 C N N P P N P N R S R S R S R S R S S S S 
  
45 46 F IP 221634 U N N P N N P N R I S S S S S R S S S S S 
46 37 F OP 125030 U N N P P N P N R R S R R S S R S S S S S 
47 50 F IP 222028 U N N P N N P N R I S I S S S S S S S S S 
48 50 M IP 220060 C N N N P N N N R R S S S R R R R R S S S 
49 55 F OP 160065 U N N N P N N N R S S R S S S S S S S S S 
50 49 F IP 222231 C N N P N N P P R S S S R S R R R R S S S 
51 42 F OP 160087 U N N N P N N P S R S R R S R S R R S S S 
52 38 F IP 221830 U N P P N N P P R R S R R S R R R R S S S 
53 43 F OP 160043 U N P N P N N N R R S R R S R S R R S S S 
54 38 M IP 222343 U N P N P N P N R S S R R S R S R R S S S 
55 42 F IP 222569 U N P N N N N P R S S R R S R R R R S S S 
56 60 F OP 160427 C N P P N N P P R R R R R R R R R R R S S 
57 37 F IP 226228 U N P N P P N P R R S R R S R R R R R S S 
58 29 F OP 160614 U N P P N P P N R S S R S S S S S S S S S 
59 46 F IP 222997 U N P P P N P P R R S R R S R R R R S S S 
60 43 F IP 222813 U N P P N N P P R R S R R S R R R R S S S 
61 64 F IP 221722 C N N N P N N P R R S R R S R R R R S S S 
62 45 F OP 159018 C N P N N P P P R R S R R S R R R S S S S 
63 22 F IP 223093 C N N N P N N N R R S R R S S S S S S S S 
64 6 F IP 223194 U N P P N N N P S S S S S S R S R R R S S 
65 2 M OP 160029 U N P N N N N P S S S S S S R S S S S S S 
66 23 F IP 222652 U N P P N N P P S S S R R S R R R R R S S 
67 73 M OP 138312 C N P P N N N P R S S R R S R R R R S S S 
68 84 F IP 223497 C C P N P N P N R R R R R R R R R R R R R 
  
69 48 F OP 171093 U N P N P N P P R R S R R S R R R R S S S 
70 40 F IP 224280 U N N P N P P P R R S R R S R R R R S S S 
71 55 F OP 162004 U N P P N P P P R S S R S S S S S S S S S 
72 44 F OP 162345 U N P P P P P P R R S R R S R R R R S S S 
73 54 M IP 224576 C N N N P N P P R R S R S S R R R R S S S 
74 43 M IP 224352 C C P P N N P P R R S R S S R R R R S S S 
75 62 M IP 224837 C N N P N N N P R R S R R R R R R R R S S 
76 23 F OP 1710933 C N N N N N N N S R S R R S S S S S S S S 
77 62 F IP 224835 U N P N N N P P R R S R S S R R R R S S S 
78 42 F IP 224832 U N P P P N N N I S S S R S R S S S S S S 
79 24 F OP 162513 U N P N N P N N R I S I I S R S S S S S S 
80 82 M IP 224819 C C P P P N P P R R S R R S R R R R R S R 
81 46 F OP 125030 U N P N N N N P R I S S R S I S S S S S S 
82 55 M IP 224816 U N P N P N P N R R S R I S S R R R R S S 
83 11 F OP 162809 U N N N N P N P S S S S S S S S S S S S S 
84 29 F IP 221102 U N N N P N N N S R S R S S S S S S S S S 
85 62 M IP 225464 C C P P N P N P R R R R R S R R R R S S S 
86 56 F IP 225386 U N P N P N N P S R S R S S R R S S S S S 
87 50 F IP 225567 U N P N P N N P R R S R R S R R R R R S S 
88 62 M IP 225648 U N P P N N P P R R S R R S R R R R S S S 
89 47 F OP 163329 U N P N P N N N R R S R R S R R R R R S S 
90 65 F IP 225583 U N N P N P N P I R S R S S I R S S S S S 
91 70 M IP 225603 C C P P N N N N R R S R R S R R R R S S S 
92 50 M IP 215700 C C N P P P P N R R R R R S R R R R R S R 
  
93 45 F IP 226391 C N N N P N P P R R S R R S R R R R R S S 
94 55 M IP 226479 C N N N P N N N R R S R R S R R R R R S S 
95 31 F OP 161639 C N N P N N N P I R S I S S I S S S S S S 
96 25 F IP 227132 U N N N P P N P S R S S R S R R R R S S S 
97 21 F IP 227314 U N N N N N N P R R S R R S S R S S S S S 
98 67 F OP 164439 C C P P N P N P R R S R R S R R R R S S S 
99 65 M IP 227919 C N P P P P P P R R R R R S R R R R R S S 
100 22 F OP 1531865 C N N N P N N N S R S S R S S S S S S S S 
101 20 M IP 209902 U N N N P N N P S R S S R S R R R R S S S 
102 70 F OP 1544854 C N P P N N N P R R R R R S R R R R S S S 
103 10 F IP 213614 U N N N N N N N S S S R S S R S S S S S S 
104 68 F IP 213875 U N N N P P N P R R S R R S R R R R R S S 
105 27 F OP 157779 U N N N N N N N S S S R S S R S S S S S S 
106 70 M IP 215602 C N P N P N N P R R R R R S R R R R R S S 
107 45 F OP 153186 U N N N N P P P R R S R R S R R R R S S S 
108 58 F OP 154422 U N N N P P N P R R R S R S R R R R S S S 
109 64 M IP 215254 C C P P N N N P R R R R R S R R R R R S S 
110 80 M OP 154485 C N P N N P P N R R S R R S R R R R S S S 
111 60 M IP 215740 C C N P P N N N R R S S R S R R R R S S S 
112 67 M IP 213586 C C N P P P N P R R R R R S R R R R S S R 
113 47 F IP 217445 U N P N P P N N R R R R R S R R R R S S S 
114 62 M OP 153698 C N N N P N P P R R S R R S R R R R S S S 
115 48 M IP 215602 U N N P N N P P R R S R R S R R R R S S S 
116 57 F IP 215661 U N N P N P N P R I S R S S R R R R S S S 
  
117 42 F OP 154553 U N P N P N N N S R S S R S S I S S S S S 
118 55 M OP 155383 U N P P N P N P R R S R I S S R R R R S S 
119 52 F IP 216253 U N N P P N N N R R S R R R R R R R S S S 
120 16 M IP 216467 U N P P N P N N S R S S S S R S S S S S S 
121 2 F IP 213611 U N N N N N N N S S S S S S R S S S S S S 
122 49 F IP 216574 U N N P N P N P R R S R R S R R R R S S S 
123 85 M IP 216086 C C N N N P P P R R S R R S R R R R R R S 
124 41 F IP 215336 U N N N P N N P R R S R R S R R R R S S S 
125 35 F IP 216579 U N N P P P P N S S S R I S S I S S S S S 
126 60 M OP 177723 C N N N N N P P R R R R R S R R R R S S S 
127 54 M IP 155764 U N N P P N P P R R S R R S R R R R S S S 
128 84 M IP 254422 C N N N P N N P R R S S R R R R R R S S S 
129 67 M IP 217392 C C P P N P P P R R S S S S R R R R S R S 
130 60 F IP 216645 U N P P P N P P R R S R R S R R R R S S S 
131 58 M IP 212603 C C N P P P P P R R R R R S R R R R S S S 
132 75 M IP 217618 C N N P P N N P R R S R R S R R R R S S S 
133 75 M OP 178872 C N N P P N N P R I S R R S S R R R S S S 
134 59 F IP 217536 U N N N P P P P R I S S S S S I S S S S S 
135 80 F IP 215798 C C P P N N N N R R S R R S R R R S S S S 
136 20 F IP 219713 U N N N P N N P S S S S R S R S S S S S S 
137 70 M IP 217039 C N N P P N N N R I S R I S R R R R S S S 
138 37 F OP 156577 U N N N P P P N S R S S S S S R S S S S S 
139 58 F IP 217861 U N N N P N P N I R S R R S I R R R R S S 
140 45 M IP 245774 C N P N N P N P R R S R R S R R R R S S S 
  
141 70 F IP 245850 C N P N N N P P R R S R R S R R R R R S S 
142 72 F IP 218765 C N N N P N P N R R S R R R R R R R S S S 
143 66 F IP 245584 C N N P N N N N R R S R R S R R R R S S S 
144 56 F IP 246049 C N N N P P P P S R S R S S I R R R R S S 
145 65 M IP 246043 U N N P P N N N R R S R R S R R R R S S S 
146 46 F IP 244943 C N N N P P N P R R S S R S R R R S S S S 
147 77 M IP 229402 C C P P P P N N R R S R R S R R R R R R R 
148 55 M OP 1673149 U N P P N P N P S R S R S S I R R R S S S 
149 75 M OP 1660460 C C P P N N P N S R S R I S S R R R R S S 
150 78 M IP 230958 C N N P N P P P R R S R R S R R R R S S S 
151 54 F OP 1680288 U N N P P N P N R R S R R S R R R R S S S 
152 62 M OP 1673999 U N N N P N N N I S S R I S S R R R S S S 
153 48 F IP 230975 U N N P N N N P S R S R R S I R R R S S S 
154 50 M IP 231106 C C P P P N P P R R R R R S R R R R R S R 
155 35 M IP 231402 U N N N P P N N R R S S R S S S S S S S S 
156 55 F IP 231449 U N P N N N P N S R S R S S I R R R S S S 
157 52 F IP 231402 U N P N P P N N R R S S I S S S S S S S S 
158 49 M IP 231067 U N P P P P N P I R S R S S S R R R R S S 
159 31 F IP 231586 C N N N P N N N R R S R I S I I S S S S S 
160 64 M IP 231680 U N N P N N P P S S S S R S R R R R S S S 
161 34 F IP 230735 U N N P P N N N S I S R S S S I S S S S S 
162 47 F IP 231632 U N P P P N P P R R S R R S R R R R S S S 
163 55 F IP 232401 U N N P P P P N R R S R R S R R R R S S S 
164 40 M IP 230007 U N N P P N P P R R S R R S R R R R S S S 
  
165 32 F IP 232803 C N N N P N P P R R S R R S R R R R S S S 
166 37 F IP 233349 U N P P P P P P R R S R R S R R R R R S S 
167 41 F IP 233817 U N N N P N N P S R S R S S I R R R S S S 
168 58 M IP 233892 C N N P P N P P S R I R R S S R R R S S S 
169 39 F OP 1676747 U N P P P N N N S R S S R S S I S S S S S 
170 46 F IP 233998 U N P P P N N P S R S R R S I R R R S S S 
171 29 F IP 233434 U N N P P N P P R R S S R R S R R R R S S 
172 40 F IP 233902 U N P P N P P N R I S R S S R R R R S S S 
173 38 M IP 234307 U N N P P N N N S R S I R S R R S S S S S 
174 29 F OP 1710933 C N N P N N N N R R S S R S S I S S S S S 
175 33 F IP 233240 U N P P P P P P R R S R R S R R R R S S S 
176 25 F IP 234616 U N N P P P N N S I S R S S S R S S S S S 
177 49 F IP 234308 U N P P N P P P R R S R R R R R R R S S S 
178 41 F IP 234657 U N N P P N N P R R S R R S R R R R S S S 
179 45 F OP 1718761 U N N P P N N N S I S I S S R I S S S S S 
180 47 M IP 235415 U N P P N P P P R R S R R S R R R R S S S 
181 70 M IP 235905 C N N N P P N N S I S S S S I I S S S S S 
182 45 F IP 1728374 U N N N P N N N R I S I S S I R S S S S S 
183 32 M IP 235033 U N P P P N N P R R S R I S R R R R S S S 
184 72 M OP 1730159 C N N P P P N N R R R R R S R R R R S S S 
185 40 F IP 236642 U N P P N P P P R R S R R S R R R R S S S 
186 21 F OP 1447467 U N N P P N N N R S S R R S R S R R S S S 
187 23 F OP 1735936 C N P N N N N N R I S S I S S S S S S S S 
188 65 M IP 236365 C C N P P N N P R R S R R S R R R R S S S 
  
189 10 F OP 1737691 U N P N P N N N R S S R R S R R R R S S S 
190 50 F IP 236807 C N N N P N N N S S S R S S S I S S S S S 
191 53 M OP 1185510 C N P N P N N N R S S R R S R R S S S S S 
192 42 M IP 237495 C C P P N P P P R R R R R R R R R R R S R 
193 62 M IP 237449 U N P N P P N N R R S R S S R R R R S S S 
194 41 F OP 1367357 U N N P P N N N R R S R I S R R R R S S S 
195 37 M OP 1739436 U N N P P P N P R R S R S S R R R R S S S 
196 38 M IP 238320 C C P P P N P N R R R R R S R R R R S S S 
197 10 M OP 1748771 U N N P N P P P S R R R R R S R R R R R S 
198 75 M IP 239100 C C N P P P N P R R S R R S R R R R S S S 
199 36 F IP 237960 U N N P P P P P R R S R R R S R R S S S S 
200 65 M IP 239140 C N P P N P P N R R S R R S R R R R S S S 
201 46 M IP 238951 C C P P N N N P R R R R R R R R R R R S S 
202 61 M IP 239430 C N N N P N N N R R S I I S R S S S S S S 
203 78 F IP 239702 C N N P P P P N R R S R R S R R R R S S S 
204 40 M OP 131441 C N N P P N P N R I S I S S S I S S S S S 
205 56 F IP 239860 C C P P N P P N R R R R R S R R R R R R S 
206 45 F IP 239810 U N N P P N N N R R S S S S S R S S S S S 
207 12 F IP 240117 U N N P P N P P S R S S R S S S R R S S S 
208 60 F IP 239979 U N N N P N N N R I S R S S I S S S S S S 
209 73 M IP 240522 C C P P N N P P R R R R R R R R R R R S R 
210 29 F IP 240285 U N N N P N N P R R S R S S S R R R S S S 
211 65 F IP 240180 U C N P P N N P R R S R R S R R R R S S S 
212 55 F IP 240742 U N N N N N N N R R S I S S R I S S S S S 
  
213 46 M IP 240800 U N N P P N N P R R S R S S R R R R S R S 
214 60 F IP 240731 U N N P N N N N R R S R S S I S S S S S S 
215 62 F IP 240846 C C P N P P P P R R R R R R R R R R R R S 
216 70 M IP 240740 C N P N N N N P R S S R S S R R R R S S S 
217 59 M IP 240799 C N P N P N N P S I S R S S I S S S S S S 
218 69 M IP 240633 U N N P P N N N R S S R I S I R S S S S S 
219 1 M IP 240400 U N P P P P N P S S S S S S S R S S S S S 
220 33 M IP 240888 U N N N N P N P R R S R R S S R R R S S S 
221 40 F OP 1664840 C C P P N N P P R R R R R S R R R R R S R 
222 73 F IP 240584 U N N P P N N N R R S R S S R R S S S S S 
223 80 M IP 241120 C N P P P N N N R R S R S S R R S S S S S 
224 86 M IP 241297 C N N P P P P P R R R R R S R R R R S R S 
225 4 F IP 241723 U N N P N N N N S R S S S S S S S S S S S 
226 65 F OP 1776939 C N P P P P P P R R S R S S R R R R R S S 
227 80 M IP 241899 U N N P P N N N R R S R R S R R S S S S S 
228 66 F IP 241849 C N N N P P N P R R S R R S R R S S S S S 
229 60 F IP 241848 C C P P P N P P R R S S R S R R R R R S S 
230 72 F IP 241839 U N N N P P N P R R S R R R R R R R R R S 
231 24 F OP 1780444 U N N P P N N P R I S R S S I S S S S S S 
232 30 M OP 1770729 U N N P P P N P R R S R R S R R R R S S S 
233 49 M IP 243311 U N N P P P N P R R S R R S R S R R S S S 
234 70 M IP 242643 C N P P P N P P R R S R R S R R R R S R S 
235 60 M OP 1081164 C N P N N N N N R R S R R S R R R R R S S 
236 54 F OP 1140540 C N P P N N N P R I S R R S R R R R S S S 
  
237 26 F OP 1762806 C N N N P N N P R R S R R S R S R R S S S 
238 70 F IP 243916 U N P P N P N N R I S S S S S I S S S S S 
239 72 M IP 243873 U N N P P P N P R R S R R R R R R R R S S 
240 75 M IP 243717 U N N N N P N N S R S R S S R R S S S S S 
241 27 M OP 1795237 U N P P N P N P S R S S S S R S S S S S S 
242 20 M OP 1794452 U N P N P P N N S R S S S S R S S S S S S 
243 48 M IP 244265 U C P P P P N P R R S S R S R R R R S S S 
244 26 F OP 1800728 C N N N N N N P R R S R S S S R R R S S S 
245 31 F OP 1784549 C N P P N N P P R R S R S S S R R R S S S 
246 60 F IP 244919 U N N P P P P P R R S S R S R R R R S S S 
247 30 F IP 245089 U N N N P N N N S R S S S S S R S S S S S 
248 60 F IP 245240 C C P P N P N P R R S R R R R R R R R R R 
249 55 F IP 244814 U N N N P N N N R R S S S S S R S S S S S 
250 70 M IP 2452455 C N N P P P P P R R S R R S R R R R S S S 
251 48 F IP 245466 C N N P P N P P R R S R R S S R R R S S S 
252 50 M IP 245433 U N N P N P N P R I S R S S R R R R S S S 
253 65 M IP 245200 C C P P P N P P R R S R R R R R R R R S S 
254 65 F IP 245264 C N P P P P N P R I S R S S R R R R S S S 
255 66 F IP 245584 U N N N P N N N R I S S S S R I S S S S S 
256 48 F IP 248166 C C P P P N N P R R S R S S R R R R S S S 
257 70 M IP 247884 U N N P N N P P R R S R S S R R R R S S S 
258 42 F IP 248096 U N N N N N N N R R S S S S S S S S S S S 
259 54 F IP 247981 C C P P N N N P R R S S R S R R R R R S S 
260 52 M IP 246329 U N N P P N N P R R S R S S R R S S S S S 
  
 
 
 
 
261 50 M IP 247988 U N N P P P P P R R S R S S R R R R S S S 
262 55 M IP 247699 U N N P N N N P S S S I S S I I S S S S S 
263 45 F IP 247462 U N N P P P P P R R S R R S R R R R S S S 
264 57 M IP 247326 U N P N P N N N I R S S S S S S S S S S S 
265 35 M IP 247420 U N N N P N N P S R S S S S S S S S S S S 
266 50 M IP 247072 C N N N P N P P R R S R S R R R R R S R S 
267 48 F IP 247061 C N P N P P N P R R S S R S R R R R R S S 
268 62 M IP 246930 C C P N P P N N R R R R R R R R R R R R R 
269 78 M IP 246617 C N N N P N N N R R S S S S R R R R S S S 
270 75 M IP 246718 C C P N P P P P R R S R R S R R R R R R S 
271 41 F IP 246085 U N P N N N N P R R S R S S R R R R S S S 
272 77 F IP 246182 U N P P N N N N R R S R S S R R R R S S S 
273 46 F IP 244943 U N N P N N N N R R S S S S R S S S S S S 
274 65 F IP 246043 U N P N P N N P R S S R S S R R R R S S S 
275 56 F IP 246049 U N N P N N N N R R S R I S S R R R S S S 
276 66 F IP 245584 C C P P P N P P R R S S R S R R R R S S S 
277 70 F IP 245850 C N N P P P N P R R R R R R R R R R R R R 
278 44 F IP 245774 U N N P N N P N S R I S S S R S S S S S S 
Key to master chart 
CD- Clinical Diagnosis 
S- Sample 
BIO- Biofilm 
SR- Serum Resistance 
GEL- Gelatinase 
SID- Siderophore 
HEM-Hemolysis 
HAI- Haemagglutination Inhibition Assay 
AMP-Ampicillin 
AMC-Amoxyclav 
GEN-Genatmycin 
AK-Amikacin 
CIP-Ciprofloxacin 
NIT-Nitrofurantoin 
COT-Cotrimoxazole 
CTR-Ceftriaxone 
CTX-Cefotaxime 
CAZ-Ceftazidime 
CPM-Cefipime 
PIT-Piperacillin-Tazobactam 
IMP-Imipenem 
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